Hims & Hers Health (HIMS) POS AM 2 Jun 21 Prospectus update (post-effective amendment) Financial data

Cover Page

Cover Page	3 Months Ended
	Mar. 31, 2021
Document Information [Line Items]
Document Type	POS AM
Amendment Flag	true
Entity Registrant Name	Hims & Hers Health, Inc.
Entity Central Index Key	0001773751
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Amendment Description	On February 5, 2021, the registrant filed a Registration Statement on Form S-1 (Registration No. 333-252814), as amended on February 11, 2021, which was subsequently declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 12, 2021 (as amended, the “Registration Statement”). On March 22, 2021, the registrant filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Original Filing”). On April 30, 2021, the registrant filed an Annual Report on Form 10-K/A, which includes the information required by Part III of Form 10-K (“Amendment No. 1”), and on May 17, 2021, the registrant filed an Annual Report on Form 10-K/A to restate the financial statements and related footnote disclosures as of December 31, 2020 and 2019 (“Amendment No. 2”). This post-effective amendment (the “POSAM”) is being filed to update the Registration Statement to (i) include information contained in Amendment No. 2 for the year ended December 31, 2020, and (ii) update certain other information in the Registration Statement. No additional securities are being registered under the POSAM. All applicable registration fees were paid at the time of the original filing of the Registration Statement.

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 88,169,000	$ 27,344,000
Short-term investments	235,097,000	72,864,000
Prepaid expenses	8,650,000	2,691,000
Inventory	4,523,000	3,543,000
Prepaid expenses and other current assets	12,407,000	5,404,000
Deferred transaction costs	0	3,929,000
Total current assets	340,196,000	113,084,000
Restricted cash, noncurrent	856,000	1,006,000
Other long-term assets	4,848,000	4,607,000
Total assets	345,900,000	118,697,000
Current liabilities:
Accounts payable	13,233,000	8,066,000
Accrued expenses	5,823,000	4,984,000
Accrued liabilities	5,823,000	4,984,000
Deferred revenue	624,000	1,272,000
Warrant liabilities	0	906,000
Total current liabilities	19,680,000	15,228,000
Deferred legal fees		150,000	$ 150,000
Warrant liabilities	33,370,000
Deferred rent, noncurrent	384,000	381,000
Total liabilities	53,434,000	15,609,000
Mezzanine equity:
Temporary Equity	0	249,962,000
Total mezzanine equity	0	249,962,000
Shareholders' equity:
Ordinary shares value	18,000
Additional paid-in capital	515,216,000	24,429,000
Accumulated other comprehensive loss	(72,000)	(11,000)
(Accumulated deficit) retained earnings	(222,696,000)	(171,292,000)
Total shareholders' equity	292,466,000	(146,874,000)	(139,793,000)
Total liabilities and shareholders' equity	$ 345,900,000	118,697,000
Restated [Member]
Current assets:
Cash and cash equivalents		1,058,267	1,510,341
Prepaid expenses		50,100	147,500
Total current assets		1,108,367	1,657,841
Investments held in Trust Account		204,525,055	203,107,342
Total assets		205,633,422	204,765,183
Current liabilities:
Accounts payable		48,194	18,475
Accrued expenses		4,189,620	478,577
Accrued liabilities		4,189,620	478,577
Accrued expenses – related party		60,000	54,839
Due to related parties		598,833	427,503
Total current liabilities		4,896,647	979,394
Deferred underwriting commissions		7,043,750	7,043,750
Deferred legal fees		150,000	150,000
Warrant liabilities		47,571,334	10,349,417
Total liabilities		59,661,731	18,522,561
Commitments and contingencies
Mezzanine equity:
Temporary Equity		140,971,690	181,242,620
Shareholders' equity:
Preferred shares value
Additional paid-in capital		40,270,527	0
(Accumulated deficit) retained earnings		(35,271,633)	4,999,298
Total shareholders' equity		5,000,001	5,000,002
Total liabilities and shareholders' equity		205,633,422	204,765,183
Common Class A [Member] | Restated [Member]
Shareholders' equity:
Ordinary shares value		604	201
Total shareholders' equity		604	201
Common Class B [Member] | Restated [Member]
Shareholders' equity:
Ordinary shares value		503	503
Total shareholders' equity		$ 503	$ 503

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Preferred stock shares authorized		1,000,000
Preferred stock, shares issued			0
Preferred stock shares outstanding			0
Temporary stock par value	$ 0.0001	$ 0.0001
Temporary shares authorized	275,000,000	95,997,674
Temporary shares issued	0	93,328,118
Temporary shares outstanding	0	93,328,118
Liquidation preference	$ 0	$ 268,452
Restated [Member]
Preferred stock par value		$ 0.0001	$ 0.0001
Preferred stock shares authorized		1,000,000	1,000,000
Preferred stock, shares issued		0	0
Preferred stock shares outstanding		0	0
Common Class A [Member]
Temporary shares outstanding		14,097,169	18,124,262
Common stock, par value	$ 0.0001	$ 0.0001
Common stock shares authorized	2,750,000,000	500,000,000
Common stock shares issued	182,973,780	46,025,754
Common stock, shares outstanding	182,973,780	46,025,754
Common Class A [Member] | Restated [Member]
Temporary equity redemption price		$ 10	$ 10
Temporary stock par value		$ 0.0001	$ 0.0001
Temporary shares authorized		500,000,000	500,000,000
Temporary shares outstanding		14,097,169	18,124,262
Common stock, par value		$ 0.0001	$ 0.0001
Common stock shares authorized		500,000,000	500,000,000
Common stock shares issued		6,027,831	2,000,738
Common stock, shares outstanding		6,027,831	2,000,738
Common Class B [Member]
Common stock, par value		$ 0.0001
Common stock shares authorized		50,000,000
Common stock, shares outstanding		5,031,250	5,031,250
Common Class B [Member] | Restated [Member]
Common stock, par value		$ 0.0001	$ 0.0001
Common stock shares authorized		50,000,000	50,000,000
Common stock shares issued		5,031,250	5,031,250
Common stock, shares outstanding		5,031,250	5,031,250
Common Class V [Member]
Common stock, par value	$ 0.0001
Common stock shares authorized	10,000,000
Common stock shares issued	8,377,623
Common stock, shares outstanding	8,377,623
Common Class F [Member]
Common stock, par value		$ 0.0001
Common stock shares authorized		6,941,352
Common stock shares issued		6,941,352
Common stock, shares outstanding		6,941,352

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2020
Revenue	$ 52,314,000	$ 30,063,000
Cost of revenue	12,067,000	9,444,000
Gross profit	40,247,000	20,619,000
Operating expenses:
Marketing	26,958,000	12,773,000
Selling, general, and administrative	61,698,000	14,064,000
Total operating expenses	88,656,000	26,837,000
Loss from operations	(48,409,000)	(6,218,000)
Other income (expense):
Interest expense	0	(10,000)
Other (expense) income, net	(2,905,000)	230,000
Loss before provision for income taxes	(51,314,000)	(5,998,000)
Change in fair value of warrant liability	(2,681,000)	71,000
Provision for income taxes	(90,000)	(35,000)
Net (loss) income	(51,404,000)	(6,033,000)
Other comprehensive loss	(61,000)	(42,000)
Total comprehensive loss	$ (51,465,000)	$ (6,075,000)
Basic and diluted net income per share	$ (0.34)	$ (0.17)
Weighted average shares outstanding, basic and diluted	153,080,538	34,610,061
Restated [Member]
Operating expenses:
General and administrative expenses			$ 1,310,755	$ 4,791,727
Loss from operations			(1,310,755)	(4,791,727)
Other income (expense):
Other (expense) income, net			1,857,342	1,742,713
Change in fair value of warrant liability			5,503,291	(37,221,917)
Net (loss) income			6,049,878	(40,270,931)
Class A Ordinary Shares [Member]
Other income (expense):
Other (expense) income, net			$ 1,500,000	$ 1,400,000
Net (loss) income	$ (49,185,000)	$ (4,823,000)
Class A Ordinary Shares [Member] | Restated [Member]
Other income (expense):
Basic and diluted net income per share			$ 0.08	$ 0.07
Weighted average shares outstanding, basic and diluted			20,125,000	20,125,000
Class B Ordinary Shares [Member]
Other income (expense):
Net (loss) income			$ (6,000,000)	$ (40,300,000)
Class B Ordinary Shares [Member] | Restated [Member]
Other income (expense):
Basic and diluted net income per share			$ 0.90	$ (8.29)
Weighted average shares outstanding, basic and diluted			5,031,250	5,031,250

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficit - USD ($)	Total	As Previously Reported	Restated [Member]	Class A Ordinary Shares [Member]	Class A Ordinary Shares [Member]Restated [Member]	Class B Ordinary Shares [Member]	Class B Ordinary Shares [Member]Restated [Member]	Redeemable Convertible Preferred Stock [Member]	Redeemable Convertible Preferred Stock [Member]As Previously Reported	Redeemable Convertible Preferred Stock [Member]Restatement Adjustment	Redeemable Class A Common Stock [Member]	Redeemable Class A Common Stock [Member]As Previously Reported	Redeemable Class A Common Stock [Member]Restatement Adjustment	Common Stock [Member]	Common Stock [Member]As Previously Reported	Common Stock [Member]Restatement Adjustment	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]As Previously Reported	Additional Paid-in Capital [Member]Restatement Adjustment	Additional Paid-in Capital [Member]Restated [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]As Previously Reported	Accumulated Deficit [Member]Restated [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Other Comprehensive Income (Loss) [Member]As Previously Reported
Beginning Balance at Apr. 08, 2019			$ 0		$ 0		$ 0													$ 0			$ 0
Beginning Balance (shares) at Apr. 08, 2019					0		0
Net income (Loss)		$ 419,439
Ending Balance at Sep. 30, 2019		5,000,006
Beginning Balance at Apr. 08, 2019			0		$ 0		$ 0													0			0
Beginning Balance (shares) at Apr. 08, 2019					0		0
Issuance of Class B ordinary shares to Sponsor			25,000				$ 503													24,497
Issuance of Class B ordinary shares to Sponsor (shares)							5,013,250
Sale of units in initial public offering, net of fair value of public warrants			191,422,292		$ 2,013															192,470,859			(1,050,580)
Sale of units in initial public offering, net of fair value of public warrants (shares)					20,125,000
Offering costs			(11,254,548)																	(11,254,548)
Shares subject to possible redemption			(181,242,620)		$ (1,812)															(181,240,808)
Shares subject to possible redemption (shares)					(18,124,262)
Issuance of PIPE shares (shares)							5,013,250
Issuance of PIPE shares			25,000				$ 503													24,497
Other comprehensive income (loss)
Net income (Loss)		1,147,262	6,049,878			$ (6,000,000)																	6,049,878
Ending Balance (shares) at Dec. 31, 2019					2,000,738		5,013,250	84,514,191			737,058			51,588,612
Ending Balance at Dec. 31, 2019	(139,793,000)	5,000,009	5,000,002		$ 201		$ 503	$ 186,741,000			$ 4,500,000						$ 13,383,000				$ (153,178,000)		4,999,298	$ 2,000
Balance as of December 31 (Shares)				18,124,262	18,124,262				186,573,651	(102,059,460)		1,627,132	(890,074)		113,887,093	(62,298,481)
Balance as of December 31,		139,793,000							$ 186,741,000			$ 4,500,000						$ 13,383,000				$ 153,178,000			$ 2,000
Issuance of Series D convertible preferred stock, net of issuance costs of $0.1 million (shares)								4,537,700
Issuance of Series D convertible preferred stock, net of issuance costs of $0.1 million								$ 31,511,000
Conversion of preferred stock to common stock (shares)											(737,058)			737,058
Conversion of preferred stock to common stock	4,500,000										$ (4,500,000)						4,500,000
Exercise of vested stock options (shares)														226
Early exercise of unvested stock options														226
Vesting of early exercised stock options	11,000																11,000
Stock-based compensation	1,404,000																1,404,000
Forfeiture of unvested early exercised shares														(46,242)
Expiration of the Class A common stock redemption right (shares)											(737,058)			737,058
Expiration of the Class A common stock redemption right	4,500,000										$ (4,500,000)						4,500,000
Other comprehensive income (loss)	(42,000)																							(42,000)
Net income (Loss)	(6,033,000)	1,334,022		$ (4,823,000)																	(6,033,000)
Ending Balance (shares) at Mar. 31, 2020								89,051,891			0			52,279,880
Ending Balance at Mar. 31, 2020	(139,953,000)	5,000,001						$ 218,252,000			$ 0			$ 0			19,298,000				(159,211,000)			(40,000)
Beginning Balance at Dec. 31, 2019	(139,793,000)	5,000,009	5,000,002		$ 201		$ 503	$ 186,741,000			$ 4,500,000						13,383,000				(153,178,000)		4,999,298	2,000
Beginning Balance (shares) at Dec. 31, 2019					2,000,738		5,013,250	84,514,191			737,058			51,588,612
Net income (Loss)		1,247,246
Ending Balance at Jun. 30, 2020		5,000,005
Beginning Balance at Dec. 31, 2019	(139,793,000)	5,000,009	5,000,002		$ 201		$ 503	$ 186,741,000			$ 4,500,000						13,383,000				(153,178,000)		4,999,298	2,000
Beginning Balance (shares) at Dec. 31, 2019					2,000,738		5,013,250	84,514,191			737,058			51,588,612
Net income (Loss)		(1,009,526)
Ending Balance at Sep. 30, 2020		5,000,003
Beginning Balance at Dec. 31, 2019	(139,793,000)	5,000,009	5,000,002		$ 201		$ 503	$ 186,741,000			$ 4,500,000						13,383,000				(153,178,000)		4,999,298	2,000
Beginning Balance (shares) at Dec. 31, 2019					2,000,738		5,013,250	84,514,191			737,058			51,588,612
Shares subject to possible redemption			40,270,930		$ 403															40,270,527
Shares subject to possible redemption (shares)					4,027,093
Other comprehensive income (loss)
Net income (Loss)		(3,049,014)	(40,270,931)			$ (40,300,000)																	(40,270,931)
Ending Balance (shares) at Dec. 31, 2020					6,027,831		5,013,250	93,328,118			0			52,967,106
Ending Balance at Dec. 31, 2020	(146,874,000)	5,000,005	5,000,001		$ 604		$ 503	$ 249,962,000			$ 0			$ 5,000			24,424,000			40,270,527	(171,292,000)		(35,271,633)	(11,000)
Beginning Balance at Mar. 31, 2020	$ (139,953,000)	5,000,001						$ 218,252,000			$ 0			$ 0			19,298,000				(159,211,000)			(40,000)
Beginning Balance (shares) at Mar. 31, 2020								89,051,891			0			52,279,880
Net income (Loss)		(86,776)
Ending Balance at Jun. 30, 2020		5,000,005
Net income (Loss)		(2,256,772)
Ending Balance at Sep. 30, 2020		5,000,003
Balance as of December 31 (Shares)	93,328,118			14,097,169	14,097,169				206,031,290	(112,703,172)					116,930,602	(63,963,496)
Balance as of December 31,	$ 249,962,000	146,874,000							$ 249,962,000							$ 5,000		$ 24,429,000	$ 5,000			$ 171,292,000			$ 11,000
Beginning Balance at Dec. 31, 2020	(146,874,000)	$ 5,000,005	$ 5,000,001		$ 604		$ 503	$ 249,962,000			$ 0			$ 5,000			24,424,000			$ 40,270,527	(171,292,000)		$ (35,271,633)	(11,000)
Beginning Balance (shares) at Dec. 31, 2020					6,027,831		5,013,250	93,328,118			0			52,967,106
Issuance of Class B ordinary shares to Sponsor	75,000,000													$ 1,000			74,999,000
Issuance of Class B ordinary shares to Sponsor (shares)														7,500,000
Pre-closing stock repurchase, net of exercise of vested options (shares)								(206,511)						(1,817,519)
Pre-closing stock repurchase, net of exercise of vested options	(21,902,000)							$ (125,000)									(21,902,000)
Conversion of preferred stock to common stock (shares)								(93,121,607)						93,121,607
Conversion of preferred stock to common stock	249,837,000							$ (249,837,000)						$ 9,000			249,828,000
Repayment of related-party promissory notes associated with vested shares	854,000																854,000
Forfeiture of related-party promissory notes														(370,734)
Conversion of Series D preferred stock warrants to Class A common warrants	1,160,000																1,160,000
Exercise of Class A common stock warrants (shares)														1,867,292
Exercise of Class A common stock warrants	21,678,000																21,678,000
Issuance of common stock upon Merger, net of transaction costs and Merger warrants liability (shares)														23,892,244
Issuance of common stock upon Merger, net of transaction costs and Merger warrants liability	129,659,000													$ 2,000			129,657,000
Issuance of PIPE shares (shares)														7,500,000
Issuance of PIPE shares	75,000,000													$ 1,000			74,999,000
Issuance of earn-out shares to common stockholders (shares)														14,153,520
Issuance of earn-out shares to common stockholders	1,000													$ 1,000
Exercise of vested stock options	80,000																80,000
Exercise of vested stock options (shares)														37,887
Vesting of early exercised stock options	54,000																54,000
Warrant expense in connection with Merger	154,000																154,000
Stock-based compensation	34,230,000																34,230,000
Expiration of the Class A common stock redemption right (shares)								(93,121,607)						93,121,607
Expiration of the Class A common stock redemption right	249,837,000							$ (249,837,000)						$ 9,000			249,828,000
Other comprehensive income (loss)	(61,000)																							(61,000)
Net income (Loss)	(51,404,000)			$ (49,185,000)																	(51,404,000)
Ending Balance (shares) at Mar. 31, 2021								0			0			191,351,403
Ending Balance at Mar. 31, 2021	$ 292,466,000							$ 0			$ 0			$ 18,000			$ 515,216,000				$ (222,696,000)			$ (72,000)
Balance as of December 31 (Shares)	0
Balance as of December 31,	$ 0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficit (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Payments of Stock Issuance Costs	$ 89
Redeemable Convertible Preferred Stock [Member]
Payments of Stock Issuance Costs	$ 100

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2020
Cash flows from operating activities:
Net (loss) income	$ (51,404,000)	$ (6,033,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	394,000	180,000
Stock-based compensation	34,230,000	1,404,000
Change in fair value of warrant liabilities	2,681,000	(71,000)
Warrant expense in connection with Merger	154,000	0
Amortization of debt issuance costs	144,000	84,000
Noncash other	452,000	(16,000)
Unrealized gain on investments (net), dividends and interest, held in Trust Account	2,905,000	(230,000)
Changes in operating assets and liabilities:
Inventory	(980,000)	(2,000,000)
Prepaid expenses and other current assets	(7,147,000)	(471,000)
Other long-term assets	(58,000)	733,000
Accounts payable	5,117,000	674,000
Accrued liabilities	1,114,000	199,000
Deferred revenue	(648,000)	126,000
Deferred rent	3,000	0
Net cash used in operating activities	(15,948,000)	(5,191,000)
Investing activities
Purchases of investments	(172,021,000)	(17,642,000)
Maturities of investments	9,500,000	19,200,000
Proceeds from sales of investments	0	6,400,000
Investment in website development and internal-use software	(740,000)	(452,000)
Purchases of property, equipment, and intangible assets	(63,000)	(273,000)
Net cash (used in)/provided by investing activities	(163,324,000)	7,233,000
Financing activities
Proceeds received from private placement	75,000,000	0
Payments of stock issuance costs	(12,794,000)	(89,000)
Proceeds from issuance of redeemable convertible preferred stock	0	31,600,000
Pre-closing stock repurchase	(22,027,000)	0
Proceeds from issuance of common stock upon Merger	197,686,000	0
Repayment of promissory notes associated with vested and unvested shares	1,193,000	0
Proceeds from exercise of Class A common stock warrants	807,000	0
Proceeds from exercise of vested and unvested stock options, net of repurchases	80,000	(18,000)
Repayments of principal on term loan	0	(1,158,000)
Net cash provided by financing activities	239,945,000	30,335,000
Foreign currency effect on cash and cash equivalents	2,000	(9,000)
Increase in cash, cash equivalents, and restricted cash	60,675,000	32,368,000
Cash, cash equivalents, and restricted cash at beginning of the year	28,350,000	22,797,000		$ 22,797,000
Cash, cash equivalents, and restricted cash at end of the three-month period	89,025,000	55,165,000	$ 22,797,000	28,350,000
Cash, beginning of period	27,344,000
Cash, end of period	88,169,000			27,344,000
Supplemental disclosures of cash flow information
Cash paid for taxes	59,000	69,000
Cash paid for interest	0	8,000
Noncash investing and financing activities:
Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase	125,000	0
Conversion of redeemable convertible preferred stock to common stock	249,837,000	0
Assumption of Merger warrants liability	51,814,000	0
Exercise of Private Placement Warrants and Public Warrants	20,871,000	0
Reclassification of deferred transaction costs	3,929,000	0
Conversion of Series D preferred stock warrants to Class A common warrants	1,160,000	0
Change in transaction costs payable	511,000	0
Vesting of early exercised stock options	54,000	11,000
Expiration of Class A common stock redemption right	0	4,500,000
Restated [Member]
Cash flows from operating activities:
Net (loss) income			6,049,878	(40,270,931)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liabilities			(5,503,291)	37,221,917
Unrealized gain on investments (net), dividends and interest, held in Trust Account			(1,857,342)	(1,742,713)
Warrant offering cost			600,675
Changes in operating assets and liabilities:
Prepaid expenses			(147,500)	97,400
Accounts payable			450,081	(6,645)
Accrued liabilities			18,475	4,171,145
Accrued expenses – related party			54,839	(418,577)
Due to related parties			92,503	171,330
Net cash used in operating activities			(241,682)	(777,074)
Investing activities
Proceeds received from sales; redemptions of marketable securities held in Trust Account				325,000
Principal deposited in Trust Account			(201,250,000)
Net cash (used in)/provided by investing activities			(201,250,000)	325,000
Financing activities
Proceeds received from initial public offering, gross			201,250,000
Proceeds received from private placement			6,025,000
Payments of stock issuance costs			(4,211,257)
Repayments of Related Party Debt			(61,720)
Net cash provided by financing activities			203,002,023
Net change in cash			1,510,341	(452,074)
Cash, beginning of period	$ 1,058,267	$ 1,510,341		1,510,341
Cash, end of period			1,510,341	1,058,267
Noncash investing and financing activities:
Change in value of Class A ordinary shares subject to possible redemption			181,242,620	$ (40,270,930)
Initial fair value of warrant liability			(15,852,708)
Offering costs included in accrued expenses			28,496
Offering costs paid by related parties			396,720
Deferred underwriting commissions in connection with the initial public offering			7,043,750
Deferred legal fees in connection with the initial public offering			150,000
Offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares			$ 25,000

Description of Organization, Bu

Description of Organization, Business Operations and Basis of Presentation	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Description of Organization Business Operations and Basis of Presentation [Abstract]
Description of Organization, Business Operations and Basis of Presentation	1. Organization Hims & Hers Health, Inc. (the “Company”), formerly known as Oaktree Acquisition Corp. (“OAC”), is a direct-to-customer easy-to-use, The Company offers a range of health and wellness products and services available for purchase directly by customers on the Company’s websites and through wholesale partners. On January 20, 2021 (the “Closing Date”), OAC completed the acquisition of Hims, Inc. (“Hims”) pursuant to the Agreement and Plan of Merger dated as of September 30, 2020 (the “Merger Agreement”) by and among OAC, Hims, and Rx Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of OAC (“Merger Sub”). The Merger Agreement provided for, among other things, the combination of Hims and OAC pursuant to the merger of Merger Sub with and into Hims, with Hims continuing as the surviving entity and as a wholly-owned subsidiary of OAC (the “Merger”). The Merger was accounted for as a reverse recapitalization with Hims as the accounting acquirer and OAC as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the unaudited condensed consolidated financial statements represents the accounts of Hims and its wholly owned subsidiaries as if Hims is the predecessor to the Company. The shares and net loss per common share, prior to the Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Merger (0.4530 shares of Company Class A common stock for 1 share of Hims Class A common stock). Prior to the Merger, OAC ordinary shares and warrants were traded on the New York Stock Exchange (“NYSE”) under the ticker symbols “OAC” and “OAC WS”, respectively. On the Closing Date, the Company’s Class A common stock and warrants began trading on the NYSE under the ticker symbols “HIMS” and “HIMS WS”, respectively. One of the primary purposes of the Merger was to provide a platform for Hims to gain access to the U.S. capital markets. See Note 3 – Recapitalization for additional details.	Note 1—Description of Organization, Business Operations and Basis of Presentation Oaktree Acquisition Corp. (now known as Hims & Hers Health, Inc.) (the “Company”) was incorporated as a Cayman Islands exempted company on April 9, 2019. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating its Business Combination, the Company intends to capitalize on the ability of its management team to identify, acquire and manage a business in the industrial and consumer sectors. The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. As of December 31, 2020, the Company had not commenced any operations. All activity for the period from April 9, 2019 (inception) through December 31, 2020 relates to the Company’s formation, the preparation for its initial public offering (the “Initial Public Offering”), as described below, and since the closing of the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating The Company’s sponsor is Oaktree Acquisition Holdings, L.P., a Cayman Islands exempted limited partnership (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on July 17, 2019. On July 22, 2019, the Company consummated its Initial Public Offering of 20,125,000 units (the “Units”), including 2,625,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, which is discussed in Note 3, generating gross proceeds of $201.25 million, and incurring offering costs of approximately $11.9 million, inclusive of approximately $7.04 million in deferred underwriting commissions (Note 5). Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) of 4,016,667 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant with the Sponsor, generating gross proceeds of approximately $6.03 million (Note 4). Upon the closing of the Initial Public Offering and the Private Placement, $201.25 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (the “Trust Account”), located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company acting as trustee, and was invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company provides the holders (the “Public Shareholders”) of its Class A ordinary shares, par value $0.0001 (the “Class A ordinary shares”), sold in the Initial Public Offering (the “Public Shares”), with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share). The per-share amount to be distributed Notwithstanding the foregoing, the Amended and Restated Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), is restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. The Company’s Sponsor, officers and directors (the “initial shareholders”) have agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, or July 22, 2021, (the “Combination Period”) or (b) with respect to any other provision relating to shareholders’ rights or pre-initial If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, The initial shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party, including any vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all third parties, including vendors, service providers (excluding the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Restatement of Previously Issued Financial Statements The Company has restated its financial statements as of December 31, 2020 and 2019, for the year ended December 31, 2020 and the period from April 9, 2019 (inception) through December 31, 2019, as well as the unaudited condensed financial statements for the three month period ended March 31, 2020, the three and six month periods ended June 30, 2020, and the three and nine month periods ended September 30, 2020 and 2019, to correct misstatements in those prior periods primarily related to misstatements identified in improperly applying accounting guidance on certain warrants, recognizing them as equity instead of a warrant liability, under the guidance of Accounting Standards Codification (“ASC”) 815-40, Contracts in Entity’s Own Equity . See Note 9 for additional information regarding the errors identified and the restatement adjustments made to the financial statements. Basis of Presentation The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Liquidity As of December 31, 2020, the Company had approximately $1.1 million in its operating bank account and approximately $3.0 million of interest income available in the Trust Account for Regulatory Withdrawal (subject to an annual limit of $325,000) and for the Company’s tax obligations, if any, and a working capital deficit of approximately $3.8 million. The Company’s liquidity needs to date have been satisfied through receipt of a $25,000 capital contribution from the Sponsor in exchange for the issuance of the Founder Shares to the Sponsor, the advancement of funds by the Sponsor of approximately $62,000 to the Company to cover for offering costs in connection with the Initial Public Offering, and the proceeds from the consummation of the Private Placement not held in the Trust Account. On November 18, 2019, the Company repaid the advance in full to the Sponsor. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 4). As of December 31, 2020 and 2019, there were no amounts outstanding under any Working Capital Loan. Based on the foregoing, management believes that the Company has sufficient cash available due to consummation of a Business Combination (discussed below) and borrowing capacity from the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. Merger On January 2 0 Form 8-K and In connection with the Merger, the Company adopted a dual class stock structure pursuant to which all stockholders of the Company will hold only shares of New Hims Class A Common Stock, except for Andrew Dudum, the Chief Executive Officer and Founder of Hims, who will hold, directly or indirectly, shares of New Hims Class A Common Stock and shares of Class V common stock of the Company (the “New Hims Class V Common Stock”). Immediately following the closing of the Merger, and by virtue of Mr. Dudum’s holdings of New Hims Class A Common Stock and New Hims Class V Common Stock, Mr. Dudum is expected to hold approximately 90% of the voting power of the capital stock of the Company on a fully diluted basis. The New Hims Class V Common Stock will also be subject to a “sunset” and conversion to New Hims Class A Common Stock if Mr. Dudum (i) no longer serves in a senior executive or board role, or (ii) transfers any shares of New Hims Class V Common Stock (except for permitted transfers). In accordance with the terms and subject to the conditions of the Merger Agreement, based on an implied equity value of $1.6 billion, minus up to $75 million of cash consideration at closing to Hims stockholders at Hims’ election, plus the aggregate strike price of all Hims options and warrants, (i) each share of Hims common stock, restricted stock and preferred stock (other than dissenting shares and shares held by Hims as treasury stock (which shares will be cancelled for no consideration as part of the Merger) will be cancelled and converted into the right to receive the applicable portion of the merger consideration comprised of New Hims Class A Common Stock, earn-out shares (as described below) and warrants to acquire shares of New Hims Class A Common Stock, each as determined in the Merger Agreement, (ii) all equity awards of Hims will be assumed by the Company and converted into comparable equity awards that are settled or exercisable for shares of New Hims Class A Common Stock, earn-out restricted stock unit awards and warrant restricted stock unit awards with a value as if such Hims equity awards were exercised prior to the closing of the Merger and (iii) each warrant of Hims that is unexercised will be assumed by the Company and represent the right to receive the applicable portion of the merger consideration upon exercise of such warrant as if such warrant was exercised prior to the closing of the Merger. Each Hims equityholder will receive its applicable portion of the earn-out shares within any 20-trading day period The Merger Agreement contains representations, warranties and covenants of each of the parties thereto that are customary for transactions of this type. The Company has also taken action such that, effective immediately after the closing of the Merger, the Company’s board of directors consist of up to eight directors, which shall include the board of directors of Hims prior to the signing of the Merger Agreement plus up to four individuals to be identified at the sole discretion of Hims. In addition, the Company has agreed to adopt an equity incentive plan in an amount not to exceed 10% of the Company’s equity interests on a fully diluted basis with an annual evergreen provision in an amount not to exceed 5% on a fully diluted basis and employee stock purchase plan in an amount not to exceed 2% of the Company’s equity interests on a fully diluted basis with an annual evergreen provision in an amount not to exceed 1% on a fully diluted basis. In addition, prior to the closing of the Merger, 25.0% of the Class B ordinary shares of the Company and the Private Placement Warrants will be surrendered and forfeited by the Sponsor in accordance with the Sponsor Agreement (as defined below) and reissued to existing Hims equityholders as New Hims Class A Common Stock (or equivalent equity awards in respect thereof) and warrants to acquire shares of New Hims Class A Common Stock (or equivalent equity awards in respect thereof) as part of the merger consideration described above and the Domestication will be consummated. Sponsor Agreement Concurrently with the execution of the Merger Agreement, the Company, the Sponsor and Hims entered into a sponsor agreement (the “Sponsor Agreement”), pursuant to which the Sponsor has agreed to, among other things, (i) vote in favor of the Merger Agreement and the transactions contemplated thereby (including the Merger), (ii) surrender and forfeit 25.0 In connection with the signing of the Merger Agreement, the Company entered into subscription agreements (the “Subscription Agreements”) with certain investors (the “PIPE Investors”). Pursuant to the Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and the Company agreed to issue and sell to such investors, on the closing date, an aggregate of 7,500,000 shares of New Hims Class A Common Stock for a purchase price of $10.00 per share, for aggregate gross proceeds of $75,000,000. Registration Rights Agreement At the closing of the Merger, the Company and the Sponsor entered into a registration rights agreement (the “ Parent Registration Rights Agreement Amended and Restated Investors’ Rights Agreement Concurrently with the execution of the Merger Agreement, the Company and certain Hims Stockholders entered into an amended and restated investors’ rights agreement (the “ A&R Company Investors’ Rights Agreement during the lock-up period described

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements as of March 31, 2021 are unaudited. The condensed consolidated balance sheet as of December 31, 2020, included herein was derived from the audited consolidated financial statements as of that date. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the year ended December 31, 2020 (the “audited consolidated financial statements”). The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and reflect, in management’s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s balance sheet, results of operations, and cash flows for the three-month periods, but are not necessarily indicative of the results expected for the full fiscal year or any other period. The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany transactions and balances have been eliminated in these condensed consolidated financial statements. For the three months ended March 31, 2021 and 2020, the Company had operations primarily in the United States and immaterial operations in the United Kingdom. There have been no changes to the Company’s significant accounting policies described in the audited consolidated financial statements for the year ended December 31, 2020, that have had a material impact on these condensed consolidated financial statements and related notes. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation and recognition of warrants, and estimates in capitalization of website development and internal-use Investments Available-for-sale Available-for-sale The investments, if any, are designated as available-for-sale Other-Than-Temporary Impairment The Company’s investments are subject to a periodic impairment review. Investments are considered impaired when the fair value is below the investment’s adjusted cost basis. This would occur for marketable debt instruments when the fair value is below amortized cost and the Company intends to sell the instrument, when it is more likely than not that the Company will be required to sell the instrument before recovery of its amortized cost basis, or when the Company does not expect to recover the entire amortized cost basis of the instrument (a credit loss exists). When the Company does not expect to recover the entire amortized cost basis of the instrument, it separates other-than-temporary impairments into amounts representing credit losses, which are recognized in other (expense) income, net, and amounts related to all other factors, which are recognized in other comprehensive (loss) income on the condensed consolidated statements of operations and comprehensive loss. The Company incurred no other-than-temporary impairments on investments for the three months ended March 31, 2021 or 2020. Inventory Inventory primarily consists of finished goods and raw materials that are located at Company-managed and third-party fulfillment warehouses. Inventory is stated at the lower of cost and net realizable value and inventory cost is determined by the weighted average cost method. The Company reserves for expired, slow-moving, and excess inventory by estimating the net realizable value based on the potential future use of such inventory. Management monitors inventory to identify events that would require impairment due to slow-moving, expired, or obsolete inventory and reduces the value of inventory when required. Obsolete inventory balances are written off against the inventory allowance when management determines that the inventory cannot be sold. The Company recorded write-offs of less than $0.1 million for the three months ended March 31, 2021 and $0.1 million for the three months ended March 31, 2020. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification Topic (“ASC”) 606, Revenue from Contracts with Customers The Company’s consolidated revenue primarily comprises of online sales of health and wellness products through the Company’s website, including prescription and nonprescription products. In contracts that contain prescription products, revenue also includes medical consultation services. Additionally, starting in March 2020, the Company began selling its products to a new wholesale partner. Revenue consists of the following (in thousands): For the Three Months Ended March 31, 2021 2020 Online $ 50,680 $ 28,524 Wholesale 1,634 1,539 Total revenue $ 52,314 $ 30,063 For online revenue, the Company defines its customer as an individual who purchases products or services through the website. For wholesale revenue, Company defines its customer as a wholesale partner. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus margin-based estimates. For each of the three months ended March 31, 2021 and 2020, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups”, which are professional corporations or other professional entities owned by licensed physicians and other professional entities that engage licensed healthcare professionals (medical doctors, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 8 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, to fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with affiliated and third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) to fill prescriptions that are ordered by the Company’s customers. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, at its sole discretion, sets all listed prices charged on its website for products and services. The Company estimates refunds using the expected value method based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company has made an accounting policy election to account for shipping and handling activities performed after the control of a product has been transferred to the customer as fulfillment costs, with direct costs to ship products to customers included in cost of revenue. The Company’s contracts with customers do not contain costs to obtain or costs to fulfill contracts with customers in accordance with ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers For online sales, payment for prescription medication and nonprescription products is typically collected from the customer a few days in advance of product shipment. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the condensed consolidated balance sheets since the associated revenue will be primarily recognized within the following period. For wholesale arrangements, payments are collected in accordance with contract terms. Stock-Based Compensation The fair value of stock options, equity-classified warrants issued to vendors, and restricted stock units (“RSUs”), are measured at the grant date fair value. The fair value of employee stock options and vendor warrants are generally determined using the Black-Scholes Merton (“BSM”) option-pricing model using various inputs, including estimates of expected volatility, term, risk-free rate, and future dividends. Stock options that were granted to the Company’s Chief Executive Officer (“CEO”) with performance and market conditions and earn-out Warrant Liabilities The Company classifies Private Placement Warrants and Public Warrants (both defined and discussed in Note 14 – Common Stock) as liabilities in addition to warrants to purchase preferred stock. At the end of each reporting period, changes in fair value during the period are recognized as a component of other (expense) income, net within the consolidated statements of operations and comprehensive loss. The Company will continue to adjust the warrant liability for changes in the fair value until the earlier of a) the exercise or expiration of the warrants or b) the redemption of the warrants, at which time the warrants will be reclassified to additional paid-in Leases The Company currently leases a warehouse facility and previously leased office space under noncancelable lease agreements that are accounted for as operating leases. Rent expense is recorded on a straight-line basis over the lease term. For rent abatement and rent escalation provisions, the Company recognizes the related rent expense on a straight-line basis over the lease term. The difference between cash rent payments and the recognition of straight-line rent expense is recorded as deferred rent and amortized over the lease term. Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement Fair Value Measurement Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) right-of-use In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments available-for-sale 2018-19 2016-13 2019-04 2019-10 2019-11, 2020-02 2020-03, 2016-13. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes 2019-12 2019-12 In October 2020, the FASB issued ASU 2020-10, Codification Improvements 2020-10	Note 2—Summary of Significant Accounting Policies Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had approximately $24 and $17,000 in cash equivalents held in the Trust Account as of December 31, 2020 and 2019, respectively. Marketable Securities Held in Trust Account The Company’s portfolio of marketable securities is comprised solely of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in gain on marketable securities (net), dividends and interest, held in the Trust Account in the accompanying statement of operations. The estimated fair values of marketable securities held in the Trust Account are determined using available market information. Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of December 31, 2020 and 2019, the carrying values of cash, accounts payable, accrued expenses, and advances from related party approximate their fair values due to the short-term nature of the instruments. The Company’s portfolio of marketable securities held in the Trust Account is comprised mainly of investments in U.S. Treasury securities with an original maturity of 185 days or less. The fair value for trading securities is determined using quoted market prices in active markets. Use of Estimates The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future conforming events. Accordingly, the actual results could differ from those estimates. Offering Costs Associated with the Initial Public Offering Offering costs consist of legal, accounting, underwriting fees and other costs incurred that are directly related to the Initial Public Offering. Offering costs related to the issuance of shares were recognized in shareholders’ equity while costs associated with the warrant liabilities were charged to expense upon the completion of the Initial Public Offering on July 22, 2019. Class A Ordinary Shares Subject to Possible Redemption Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020 and 2019, 14,097,169 and 18,124,262, respectively, Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheets. Net Income Per Ordinary Share Net income per share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of 10,725,000 of the Company’s Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method. The Company’s statement of operations includes a presentation of income per share for ordinary shares subject to redemption in a manner similar to the two-class method Net income per ordinary share, basic and diluted for Class A ordinary shares are calculated by dividing the interest income earned on investments and marketable securities held in the Trust Account of approximately $1.7 million, net of $325,000 annual limit of Regulatory Withdrawal available to be withdrawn from the Trust Account, resulting in a total of approximately $1.4 million for the year ended December 31, 2020, by the weighted average number of Class A ordinary shares outstanding for the period. Net loss per ordinary share, basic and diluted for Class B ordinary shares is calculated by dividing the net loss of approximately $40.3 million, less income attributable to Class A ordinary shares of approximately $1.4 million, resulted in a net loss of approximately $41.7 million, by the weighted average number of Class B ordinary shares outstanding for the period. Net income per ordinary share, basic and diluted for Class A ordinary shares are calculated by dividing the interest income earned on investments and marketable securities held in the Trust Account of approximately $1.9 million, net of $325,000 annual limit of Regulatory Withdrawal available to be withdrawn from the Trust Account, resulting in a total of approximately $1.5 million for the period from April 9, 2019 (inception) through December 31, 20 19 in a net loss of approximately $4.5 million Warrant Liability The Company accounts for warrants for shares of the Company’s Class A ordinary shares as liabilities held at fair value on the balance sheet. The warrants are subject to remeasurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense), net on the statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants. At that time, the warrant liability will be reclassified to additional paid-in Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740, Simplifying the Accounting for Income Taxes, prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020 and 2019. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2020 and 2019. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Recent Accounting Pronouncements The Company’s management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

Recapitalization

Recapitalization	3 Months Ended
	Mar. 31, 2021
Reverse Recapitalization [Abstract]
Recapitalization	3. Recapitalization As discussed in Note 1 – Organization, on the Closing Date, OAC completed the acquisition of Hims and acquired 100% of Hims’ shares and Hims received gross proceeds of $197.7 million. Transaction costs of $16.2 million, which consist of legal, accounting, and other professional services directly related to the Merger, are included in additional paid-in earn-out As additional consideration, OAC also granted 888,143 OAC Class A common stock warrants (“Parent Warrants”) to Hims’ stockholders, 3,443 Parent Warrants to warrant holders, and approximately 35,000 RSUs to Hims’ option and RSU holders (“Parent Warrant RSUs”). All equity awards of Hims were assumed by OAC and converted into comparable equity awards that are settled or exercisable for shares of the Company’s Class A common stock. As a result, each stock option was converted into an option to purchase shares of the Company’s Class A common stock based on an exchange ratio of 0.4530. Each award of the Hims’ RSUs was converted into RSUs of the Company based on an exchange ratio of 0.4530. Similarly, all outstanding Hims warrants were converted at an exchange ratio of 0.4530. The Merger was accounted for as a reverse recapitalization with Hims as the accounting acquirer and OAC as the acquired company for accounting purposes. Hims was determined to be the accounting acquirer since Hims’ shareholders prior to the Merger had the greatest voting interest in the combined entity, Hims’ shareholders appointed the initial directors of the combined Board of Directors and control future appointments, Hims comprises all of the ongoing operations, and Hims’ senior management directs operations of the combined entity. Accordingly, all historical financial information presented in these unaudited condensed consolidated financial statements represents the accounts of Hims and its wholly owned subsidiaries as if Hims, rather than OAC, is the predecessor to the Company. No step-up Earn-Out Following the closing of the Merger, holders of Hims’ common stock and outstanding equity awards (including warrant, stock option and RSU holders) had the right to receive up to an aggregate amount of 16,000,000 shares of Company Class A common stock (or equivalent equity award) that would vest (in part) in equal thirds if the trading price of the Company’s Class A common stock was greater than or equal to $15.00, $17.50 and $20.00 for any 10 trading days within any 20-trading earn-out earn-out earn-out Distinguishing Liabilities from Equity PIPE Investment Concurrently with the execution of the Merger Agreement, OAC entered into subscription agreements on September 30, 2020 with certain investors (the “PIPE Investors”) pursuant to which such investors collectively subscribed for 7,500,000 shares of the Company’s Class A common stock at $10.00 per share for aggregate gross proceeds of $75.0 million (the “PIPE Investment”). The PIPE Investment was consummated substantially concurrently with the closing of the Merger.

Investments

Investments	3 Months Ended
	Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Investments	4. Investments Short-term investments as of March 31, 2021, consist of the following (in thousands): Adjusted Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 177,273 $ 1 $ (53 ) $ 177,221 Government bonds 40,955 2 (5 ) 40,952 Asset-backed bonds 16,928 — (4 ) 16,924 Total short-term investments $ 235,156 $ 3 $ (62 ) $ 235,097 Short-term investments as of December 31, 2020, consist of the following (in thousands): Adjusted Cost Unrealized Gains Unrealized Fair Value Corporate bonds $ 55,224 $ 5 $ (2 ) $ 55,227 Government bonds 14,121 2 — 14,123 Asset-backed bonds 3,514 — — 3,514 Total short-term investments $ 72,859 $ 7 $ (2 ) $ 72,864 Short-term investments mature within one year.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventory	5. Inventory Inventory consists of the following (in thousands): March 31, December 31, Finished goods $ 3,546 $ 2,856 Raw materials 977 687 Total inventory $ 4,523 $ 3,543

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	6. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, Trade and other receivables, net $ 942 $ 1,147 Prepaid expenses 8,650 2,691 Vendor deposits 2,810 1,395 Other current assets 5 171 Total prepaid expenses and other current assets $ 12,407 $ 5,404

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Accrued Liabilities	7. Accrued Liabilities Accrued liabilities consist of the following (in thousands): March 31, December 31, Marketing expenses $ 1,514 $ 1,122 Professional services 1,480 1,241 Payroll costs 1,250 919 Tax payables 729 651 Warrant exercise deposit liability — 664 Other accrued liabilities 850 387 Total accrued liabilities $ 5,823 $ 4,984

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	8. Variable Interest Entities In order for customers to obtain a prescription product, customers must complete a consultation with a Provider on the Company’s website through one of the Affiliated Medical Groups and receive a written prescription by the applicable Provider. The Affiliated Medical Groups and the Company do not have any shareholders in common. The Affiliated Medical Groups are 100% owned by licensed physicians. The Company is party to service agreements with the Affiliated Medical Groups pursuant to which the Company provides management and administrative services and collects the medical consultation fees from customers on behalf of the Affiliated Medical Groups. In October 2020, the Company also entered into service agreements with XeCare LLC (“XeCare”), a licensed mail order pharmacy affiliated with the Company which is expected to provide prescription fulfillment services solely to the Company’s customers. The Affiliated Medical Groups and XeCare are legal entities that the Company has determined qualify as variable interest entities (“VIEs”). The Company determined that it is the primary beneficiary of these entities for accounting purposes because it has the ability to direct the activities that most significantly affect the entities’ economic performance and has the obligation to absorb the losses. Under the VIE model, the Company presents the results of operations and the financial position of the Affiliated Medical Groups and XeCare as part of the consolidated financial statements of the Company as if the consolidated group were a single economic entity. There is no noncontrolling interest upon consolidation of the entities. The results of operations and cash flows of the Affiliated Medical Groups and XeCare are also included in the Company’s condensed consolidated financial statements. As of March 31, 2021 and December 31, 2020, the Company’s condensed consolidated balance sheets included Affiliated Medical Groups and XeCare’s combined current and total assets of $0.5 million and $1.4 million. As of March 31, 2021 and December 31, 2020, current liabilities were $1.1 million and $0.8 million and total liabilities were $1.5 million and $1.2 million. All amounts are after elimination of intercompany transactions and balances. The results of operations and cash flows of the Affiliated Medical Groups and XeCare are included in the Company’s condensed consolidated financial statements. For the three months ended March 31, 2021 and 2020, the Affiliated Medical Groups and XeCare combined charged the Company $3.4 million and $0.3 million for services rendered. For the three months ended March 31, 2021 and 2020, the net losses generated by the Affiliated Medical Groups and XeCare combined were $1.8 million and $2.5 million after elimination of intercompany transactions and balances.

Fair Value Measurements

Fair Value Measurements	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. Fair Value Measurements The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 74,930 $ — $ — $ 74,930 Government bonds — 11,082 — 11,082 Short-term investments: Corporate bonds — 177,221 — 177,221 Government bonds — 40,952 — 40,952 Asset-backed bonds — 16,924 — 16,924 Restricted cash: Money market funds 856 — — 856 Total assets 75,786 246,179 — 321,965 Liabilities Warrant liabilities 33,370 — — 33,370 Total liabilities $ 33,370 $ — $ — $ 33,370 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 12,163 $ — $ — $ 12,163 Government bonds — 12,693 — 12,693 Short-term investments: Corporate bonds — 55,227 — 55,227 Government bonds — 14,123 — 14,123 Asset-backed bonds — 3,514 — 3,514 Restricted cash: Money market funds 1,006 — — 1,006 Total assets 13,169 85,557 — 98,726 Liabilities Warrant liabilities — — 906 906 Total liabilities $ — $ — $ 906 $ 906 The fair values of cash, accounts receivable, accounts payable, and accrued liabilities approximated their carrying values as of March 31, 2021 and December 31, 2020, due to their short-term nature. All other financial instruments except for warrant liabilities related to the preferred stock warrants and Private Placement Warrants are valued either based on recent trades of securities in active markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The warrant liabilities related to the preferred stock warrants and Private Placement Warrants contain significant unobservable inputs including the expected term and with respect to the preferred stock warrants, the share exchange ratio in evaluating the fair value of underlying common stock, and exercise price. Therefore, these warrant liabilities were evaluated to be a Level 3 fair value measurement. In prior periods, the fair value of the preferred stock warrant liability had been measured using the BSM option-pricing model and Monte Carlo simulation. During 2020, the Company changed its valuation method as a result of increased probability that the Company’s common shares would be publicly listed in the near-term and began using a probability weighted expected returns methodology. As of December 31, 2020, the Company reverted to using a BSM option-pricing model to determine the value of the outstanding Series D preferred stock warrants (that replaced the Series C preferred stock warrants as discussed in Note 10 – Borrowing Arrangements). Subsequent to the Merger, the Series D preferred stock warrants were converted to Class A common stock warrants. As a result, the Series D preferred stock warrants were adjusted to fair value prior to the conversion resulting in a change in fair value of $0.3 million recognized as a component of other income (expense), net within the consolidated statements of operations and comprehensive loss, and then settled in additional paid-in For the three months ended March 31, 2021, changes in warrant liabilities also related to changes in liabilities for warrants assumed as part of the recapitalization, including Private Placement Warrants and Public Warrants (defined and discussed in Note 14 – Common Stock). The Company valued the Private Placement Warrants using a Monte Carlo valuation simulation. Inherent in a Monte Carlo simulation are assumptions related to expected term, volatility, risk-free interest rate and dividend yield. The expected term of the warrants was determined to be equivalent to their remaining contractual term and includes consideration of the redemption features that were incorporated into the Monte Carlo model. The Company derived the volatility of its Class A common stock based on average historical stock volatilities of a peer group of public companies that the Company considers to be comparable to its business over a period equivalent to the expected term of the Private Placement Warrants. The risk-free interest rate is based on the U.S. Treasury’s rates of U.S. Treasury zero-coupon Expected term 0.16 Volatility 65.00 % Risk-free rate 0.03 % Dividend yield — % The Public Warrants were valued as of March 31, 2021 using the listed trading price of $4.40 per Public Warrant. The change in the fair value of warrant liabilities is as follows (in thousands): Balance at December 31, 2020 $ 906 Conversion of Series D preferred stock warrants to Class A common stock warrants (1,160 ) Private Placement Warrants and Public Warrants 51,814 Exercised warrants (20,871 ) Increase in fair value of warrants 2,681 Balance at March 31, 2021 $ 33,370 As of March 31, 2021, the Company had no transfers between levels of the fair value hierarchy of its assets or liabilities measured at fair value. Due to the exercise and conversion to Class A common stock warrants of all preferred stock warrants and exercise of all of the Private Placement Warrants during the period, there were no longer any Level 3 warrant liabilities.	Note 7—Fair Value Measurements The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and 2019 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. December 31, 2020: Description Quoted Prices in Significant Other Significant Other Assets held in Trust Account: U.S. Treasury Securities $ 204,525,031 $ — $ — Cash equivalents - money market funds 24 — — $ 204,525,055 $ — $ — Liabilities: Public Warrants $ 26,162,499 $ — $ — Private Placement Warrants — — 21,408,835 $ 26,162,499 $ — $ 21,408,835 December 31, 2019: Description Quoted Prices in Significant Other Significant Other Assets held in Trust Account: U.S. Treasury Securities $ 203,090,272 $ — $ — Cash equivalents - money market funds 17,070 — — $ 203,107,342 $ — $ — Liabilities: Public Warrants $ 6,372,917 $ — $ — Private Placement Warrants — — 3,976,500 $ 6,372,917 $ — $ 3,976,500 Level 1 instruments include investments in money market funds and U.S. Treasury securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. The estimated fair value of the Private Placement Warrants, and the Public Warrants, prior to being separately listed and traded, is determined using Level 3 inputs. The fair value of the Public Warrants and Private Placement Warrants were initially measured at fair value using a Black-Scholes Merton (“BSM”) model and subsequently, the fair value of the Private Placement Warrants were estimated using a Monte Carlo simulation model for each measurement date. The fair value of Public Warrants were subsequently measured based on the listed market price. Inherent in both the BSM and Monte Carlo models are assumptions related to expected term, volatility, risk-free interest rate and dividend yield. The expected term of the warrants is assumed to be equivalent to their remaining contractual term and includes consideration of the redemption features that were incorporated into the Monte Carlo model. The Company estimates the volatility of its ordinary shares based on historical volatility of select peer companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon The following table provides quantitative information regarding Level 3 fair value measurement inputs: December 31, 2020 2019 Expected term 0.31 1.75 Volatility 55.00 % 29.60 % Risk-free rate 0.10 % 0.14 % Dividend yield 0.00 % 0.00 % The change in the fair value of the warrant liabilities is summarized as follows: December 31, 2020 2019 Beginning balance $ 10,349,417 $ — Issuance of Public and Private Placement Warrants — 15,852,708 Change in fair value 37,221,917 (5,503,291 ) Ending balance $ 47,571,334 $ 10,349,417 Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the year ended December 31, 2020. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in September 2019 when the Public Warrants were separately listed and traded.

Borrowing Arrangements

Borrowing Arrangements	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Borrowing Arrangements	10. Borrowing Arrangements Silicon Valley Bank Under the Second Amended and Restated Loan Agreement dated November 27, 2019, between Hims and Silicon Valley Bank (“SVB”), upon Hims’ request, SVB would issue letters of credit (the “Letters of Credit”) in an aggregate amount not to exceed $2.0 million. This amount is reduced by the amount otherwise available with respect to the cash management services, which may include merchant services, direct deposit of payroll, business credit card, and check cashing services identified in SVB’s various agreements. On September 30, 2020, Hims entered into the First Loan Modification Agreement (“Loan Modification Agreement”) and the aggregate amount of the Letters of Credit was amended to $3.5 million. As of March 31, 2021, SVB issued on the Company’s behalf, a letter of credit in the amount of $0.8 million as a security deposit for a warehouse space in New Albany, Ohio. SVB required $0.8 million to be maintained as collateral for the outstanding letter of credit. The Company expects to continue to renew the letter of credit through the duration of the lease. As this is for longer than one year, the Company presents the $0.8 million within restricted cash, noncurrent on the consolidated condensed balance sheet. There is a business credit card as part of the cash management services offered by SVB with an initial limit of $2.0 million which is reduced by the amount utilized for any issuances of Letters of Credit. This amount was increased to $3.5 million by the Loan Modification Agreement. To continue to use the credit card, SVB required $0.2 million to be maintained in a collateralized money market account and this was reflected within restricted cash on the consolidated balance sheet as of December 31, 2020. In January 2021, the Company terminated the Second Amended and Restated Loan Agreement with SVB resulting in the release of restricted cash of $0.2 million under the arrangement. The outstanding letter of credit for the warehouse was not included as part of this termination. In addition, the Company continues to use SVB’s cash management services and increased its credit card limit to $5.0 million in January 2021. TriplePoint Venture Growth On November 27, 2019, Hims entered into a Plain English Capital Growth and Security Agreement (the “2019 Capital Agreement”) with TriplePoint Venture Growth (“TPC”) consisting of a term loan in the aggregate principal amount of up to $50.0 million, with $25.0 million being available immediately through December 31, 2020 (the “Part 1 Commitment Amount”), and an additional $25.0 million becoming available upon utilization of the Part 1 Commitment Amount through December 31, 2020. There was no minimum advance amount. As collateral, the Company provided a second lien security interest to TPC of substantially all its assets. As of December 31, 2020, the Company had not drawn down from this term loan and the facility expired. In connection with the 2019 Capital Agreement, the Company issued to TPC a warrant granting TPC the right to purchase 89,747 shares of Hims’ Series C preferred stock at an exercise price of $7.67 per share, subject to adjustment in regard to the preferred stock series, number of shares and exercise price if the per share price of subsequent preferred stock rounds less than $7.67. On March 12, 2020, Hims sold Series D preferred stock at an issuance price of $6.96, which triggered an adjustment to the TPC warrant terms per the original agreement, resulting in conversion of the previously issued 89,747 Series C preferred stock warrants at an exercise price of $7.67 into 98,723 Series D preferred stock warrants at an exercise price of $6.96. Subsequent to the Merger, the Series D preferred stock warrants were converted to Class A common stock warrants. Refer to Note 13 – Redeemable Convertible Preferred Stock

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Leases Total rent expense for the three months ended March 31, 2021 and 2020, was $0.4 million and $0.7 million. In January 2020, the Company entered into a 63-month Future minimum lease commitments subsequent to March 31, 2021 are as follows (in thousands): 2021 $ 1,146 2022 1,559 2023 1,598 2024 1,638 2025 1,114 Total $ 7,055 Purchase Obligations As of March 31, 2021, the Company had contractual obligations to make $1.0 million in purchases related to cloud-based software contracts used in operations. Legal Proceedings From time to time, the Company is a party to various litigation, claims, and other legal and administrative proceedings arising in the ordinary course of business. Some of these claims, lawsuits, and other proceedings may involve highly complex issues that are subject to substantial uncertainties, and could result in damages, fines, penalties, nonmonetary sanctions, or relief. Management is not currently aware of any matters that are reasonably likely to have a material adverse impact on the Company’s business, financial position, results of operations, or cash flows.	Note 5—Commitments & Contingencies Registration and Shareholder Rights The holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans, if any, will be entitled to registration rights pursuant to a registration and shareholder rights agreement entered into in connection with the consummation of the Initial Public Offering. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable lock-up period for the securities Underwriting Agreement The Company granted the underwriters a 45-day option from the date The underwriters were entitled to underwriting discounts of $0.20 per unit, or $4.025 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or approximately $7.04 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. This was paid upon the close of the Merger. Deferred Legal Fees The Company entered into an engagement letter to obtain legal advisory services, pursuant to which the Company’s legal counsel agreed to defer an aggregate of $150,000 of their fees in connection with the Initial Public Offering until the closing of the Initial Business Combination. The deferred fee will become payable to the legal counsel from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination. As of December 31, 2020 and 2019, the Company recorded an aggregate of $150,000 in connection with such arrangement as deferred legal fees in the accompanying balance sheet. This was paid upon the close of the Merger.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	12. Stock-Based Compensation 2017 Stock Plan and 2020 Equity Incentive Plan In July 2017, the Company adopted the 2017 Stock Plan (the “2017 Plan”). Under the 2017 Plan, the Board of Directors could grant awards, including incentive stock options, non-statutory In January 2021, in connection with the Merger, the Board of Directors adopted the 2020 Equity Incentive Plan (the “2020 Plan”) and reserved 21,000,000 authorized shares of Class A common stock the Company could issue. In addition, up to 19,000,000 shares of Hims Class A common stock subject to awards granted under the 2017 Plan that were forfeited, expired or lapsed unexercised or unsettled could be added to the 2020 Plan reserve. Beginning on January 1, 2022 and ending on January 1, 2031, the number of authorized shares of common stock under the 2020 Plan will automatically increase by 5% of the total number of Class A and Class V common stock issued and outstanding on the last day of the preceding fiscal year unless the Board of Directors approves a lesser number. As of the effective date of the 2020 Plan, no further stock awards have been or will be granted under the 2017 Plan. During the period, 55,645 shares of Class A common stock subject to awards granted under the 2017 Plan that were outstanding on the Merger date and forfeited after the adoption of the 2020 Plan were added to the 2020 Plan reserve. Therefore, as of March 31, 2021, there were 21,055,645 shares of Class A common stock reserved and 18,581,886 shares of Class A common stock available for the Company to grant under the 2020 Stock Plan; there were no more shares available for grant under the 2017 Plan (since the 2017 Plan was replaced by the 2020 Plan). Under both the 2017 Plan and 2020 Plan, stock options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than 100% of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding 10% or more of the Company’s equity cannot be granted with an exercise price of less than 110% of the estimated fair market value of the common stock on the grant date and such options are not exercisable after five years from the grant date. Stock Options Options for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date and then 1/48th of the total grant vesting monthly thereafter. Options granted to current employees generally vest 1/48th of the total grant monthly over four years. Options granted are exercisable within a period not exceeding ten years from the grant date. On June 17, 2020, the Board of Directors granted 3,246,139 and 1,623,070 stock options to the CEO with an exercise price of $2.43 to vest upon either (i) an acquisition of the Company with per share consideration equal to at least $22.99 and $38.31, respectively, or (ii) a per share price on a public stock exchange that is at least equal to $22.99 and $38.31, respectively. The CEO is required to be employed at the time the per share consideration/price is achieved in order to receive the awards, but the awards are not subject to any other service condition. The Company recognizes expense related to these awards based on the fair value and derived service term as measured using a Monte Carlo simulation model, but only upon achieving the requirements outlined in (i) and (ii) above. The grant-date fair value was $16.6 million for these awards. The $22.99 per share price threshold related to award for the 3,246,139 stock options was achieved in February 2021 subsequent to the Merger and, therefore, the Company recognized all $11.3 million of expense related to the grant during the three months ended March 31, 2021 due to achievement of the market condition. As of March 31, 2021, there was $4.2 million of remaining compensation expense to be recognized for the remaining 1,623,070 stock options over a period of 3.04 years. In connection with the Merger, all Hims option holders received an equivalent award at an exchange ratio of 0.4530 that vest in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock-based compensation expense since the fair value of the modified awards immediately after the modification was not greater than the fair value of the original awards immediately before the modification. The grant-date fair value of the Company’s stock options granted was estimated using the following weighted average assumptions for the three months ended March 31, 2021: Expected term (in years) 5.77 Expected volatility 58.87 % Risk-free interest rate 0.83 % Expected dividend yield — % Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Average Exercise Price Weighted Average Contractual Period (in Years) Aggregate Intrinsic Value Outstanding at December 31, 2020 26,459 $ 1.16 8.50 $ 131,770 Recapitalization (14,474 ) 1.41 Outstanding at December 31, 2020 11,985 2.57 8.50 131,770 Granted 423 13.79 Exercised (including early exercised options vested during the period) (384 ) 0.90 Forfeited and expired (56 ) 1.70 Outstanding at March 31, 2021 11,968 3.02 8.37 122,556 Vested and expected to vest as of March 31, 2021 11,968 3.02 8.37 122,556 Exercisable as of March 31, 2021 11,165 $ 2.64 8.37 $ 118,231 The weighted average grant-date fair value of options granted for the three months ended March 31, 2021 was $7.34 per share and the intrinsic value of vested options exercised was $2.0 million. As of March 31, 2021, there was $20.5 million of unrecognized stock-based compensation related to unvested stock options excluding the CEO stock options, which is expected to be recognized over a weighted average period of 3.33 years. The cash flows resulting from the tax benefits for tax deductions resulting from the exercise of stock options in excess of the compensation expense recorded for those options (excess tax benefits) are classified as a cash flow from financing activities. Due to a full valuation allowance on deferred tax assets, the Company did not recognize any tax benefit from stock option exercises for the three months ended March 31, 2021. Early Exercise of Common Stock Options paid-in The options outstanding and exercisable as of March 31, 2021 (excluding CEO stock options) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Average Remaining Contractual Life (in Years) Shares Weighted Average Remaining Contractual Life (in Years) $ 0.06 – 0.40 3,236 6.92 3,123 6.92 1.55 – 2.33 3,368 8.07 3,182 8.07 2.43 – 3.65 3,298 9.17 3,295 9.17 8.90 – 13.35 1,888 9.76 1,558 9.75 15.17 – 22.76 178 9.79 7 9.78 11,968 11,165 RSUs All RSUs granted prior to the Merger were subject to achievement of a liquidity event which included (i) an initial public offering, (ii) a business combination transaction, or (iii) a sale event as defined by the 2017 Plan. On January 20, 2021, the liquidity event was achieved with the closing of the Merger. RSUs for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date on the first Company Quarterly Vesting Date (defined below) and the remaining grant vesting quarterly thereafter on the specified vesting dates of March 15, June 15, September 15 and December 15 (each, a “Company Quarterly Vesting Date” or collectively, “Company Quarterly Vesting Dates”). Additional RSUs granted to current employees generally vest quarterly on Company Quarterly Vesting Dates over four years. In connection with the Merger, all Hims RSU holders received an equivalent award at an exchange ratio of 0.4530 that vest in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock-based compensation expense since the fair value of the modified awards immediately after the modification was not greater than the fair value of the original awards immediately before the modification. In addition, all Hims RSU and option holders received (a) earn-out 20-trading The earn-out earn-out earn-out Distinguishing Liabilities from Equity earn-out Expected term (in years) 5.00 Expected volatility 60.00 % Risk-free interest rate 0.50 % Expected dividend yield — % The value of the Company’s equity was also an input into the model and was determined based on the closing trading price of the Company’s Class A common stock on the Closing Date of $16.38. RSU activity including RSUs outstanding prior to the Merger, earn-out Shares Weighted Average Grant Unvested at December 31, 2020 3,480 $ 5.30 Recapitalization (1,904 ) 5.99 Unvested at December 31, 2020 1,576 11.29 Granted 2,804 14.95 Vested (790 ) 15.66 Unvested at March 31, 2021 3,590 $ 13.16 Included in the above activity are 476,308 earn-out earn-out earn-out non-executive As of March 31, 2021, there was unrecognized stock-based compensation related to unvested RSUs of $40.1 million, which is expected to be recognized over a weighted average period of 3.61 years. Vendor Warrants Included in stock-based compensation expense is expense for issuance of Class A common stock warrants to nonemployees in connection with vendor service arrangements. In connection with the Merger, warrant holders received (a) an equivalent warrant at an exchange ratio of 0.4530 (which was determined not to result in incremental stock-based compensation expense similar to the evaluations for stock options and RSUs above); (b) the right to receive, upon exercise, earn-out 20-trading earn-out earn-out Vendor warrant activity, excluding any right to receive Merger considerations, is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2020 1,861 0.79 7.01 $ 9,957 Recapitalization (1,018 ) 0.96 Outstanding at December 31, 2020 843 1.75 7.01 $ 9,957 Granted — — Exercised (381 ) 1.75 Forfeited and expired — — Outstanding at March 31, 2021 462 1.75 7.01 $ 5,308 Vested and expected to vest as of March 31, 2021 462 1.75 7.01 $ 5,308 Exercisable as of March 31, 2021 185 1.75 7.01 $ 2,123 Upon the exercise of outstanding warrants above, vendors also have the right to receive 48,062 shares of Merger consideration, consisting of the holders’ allocation of earn-out As of March 31, 2021, there was $0.5 million of unrecognized stock-based compensation expense related to unvested vendor warrants and associated earn-out Stock-Based Compensation Expense The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the condensed consolidated statements of operations and comprehensive loss for three months ended March 31, 2021 and March 31, 2020 (in thousands): Three Months Ended March 31 2021 2020 Marketing $ 1,846 $ 291 Selling, general, and administrative 32,384 1,113 Total stock-based compensation expense $ 34,230 $ 1,404

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2021
Temporary Equity Disclosure [Abstract]
Temporary Equity [Text Block]	13. Redeemable Convertible Preferred Stock As of December 31, 2020 the Company had authorized 95,997,674 shares of Hims’ convertible preferred stock, designated in series, with the rights and preferences of each designated series to be determined by the Board of Directors. The following table is a summary of Hims’ redeemable convertible preferred stock as of December 31, 2020 (in thousands, except for share data): Series Shares Authorized Shares Issued and Outstanding Aggregate Liquidation Value Proceeds, Net of Issuance Costs Issue Price per Share Series Seed 4,987,477 4,987,477 $ — $ — $ 0.0001 Series A 23,822,492 23,822,492 6,621 5,106 0.2780 Series A-1 5,742,012 5,742,012 753 740 0.1312 Series B 13,270,590 13,270,590 24,600 23,429 1.8538 Series B-1 9,807,952 9,807,952 20,000 14,965 2.0392 Series B-2 13,464,939 13,464,939 51,371 49,911 3.8152 Series C 14,850,340 14,760,594 113,072 92,590 7.6604 Series D 10,051,872 7,472,062 52,035 51,900 6.9639 Total 95,997,674 93,328,118 $ 268,452 $ 238,641 Transactions Related to Convertible Preferred Stock From March to July 2020, a group of investors purchased 7,472,062 shares of Hims Series D redeemable convertible preferred stock and the Company received $51.9 million in net proceeds. In connection with the Merger, all series of Hims redeemable convertible preferred stock were converted into Hims’ Class A common stock on a one-for-one Warrants for Redeemable Convertible Preferred Stock In February 2020, in accordance with the terms outlined in March 2019, the Company issued 1,341,865 Hims Series C convertible preferred stock warrants based on 2019 revenue. The fair market value of the Hims Series C convertible preferred stock warrants was estimated using the BSM option-pricing model, and at the issuance date, fair value of the liability was $10.0 million. The original liability was recorded as an issuance cost for the Hims Series C preferred stock, reducing the value of the Hims Series C proceeds within mezzanine equity on the consolidated balance sheets. Subsequent adjustments to the fair value of the Hims Series C convertible preferred stock warrants were recorded within other income (expense), net on the consolidated statements of operations and comprehensive loss. The holders of the Hims Series C convertible preferred stock exercised all their warrants and purchased 1,341,865 shares of Hims Series C convertible preferred stock from the Company in 2020 resulting in settlement of the Hims Series C convertible preferred stock warrant liability. The Company received less than $0.1 million in net proceeds. Upon exercise, the warrant liability at an estimated fair market value of $11.3 million was reclassified into convertible preferred stock on the consolidated balance sheet. In November 2019, the Company issued 89,747 Hims Series C preferred stock warrants to TPC in connection with the 2019 Capital Agreement. The fair value of the warrants was considered debt issuance cost and recorded within prepaid and other current assets on the consolidated balance sheet. On March 12, 2020, the Company sold Hims Series D redeemable convertible preferred stock at an issuance price of $6.96, which triggered an adjustment to the TPC warrant terms per the original agreement, resulting in conversion of the previously issued 89,747 Hims Series C preferred stock warrants into 98,723 Hims Series D preferred stock warrants. Refer to Note 10 – Borrowing Arrangements for further discussion. Subsequent to the Merger, the Hims Series D preferred stock warrants were converted to Class A common stock warrants. As a result, the Hims Series D preferred stock warrants were adjusted to fair value prior to the conversion, and then settled in additional paid-in

Common Stock

Common Stock	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Common Stock	14. Common Stock Prior to the Merger, the Company had two classes of authorized common stock, Hims Class A common stock and Hims Class F common stock. Shares issued on early exercise are not considered outstanding for accounting purposes because the employees holding these awards are not entitled to the rewards of stock ownership. The rights of the holders of Hims Class A and Hims Class F common stock were identical, except with respect to (i) electing members of the Board of Directors and (ii) voting rights. The outstanding shares of Hims Class A and Hims Class F common stock presented on the consolidated balance sheet and on the consolidated statement of mezzanine equity and stockholders’ equity (deficit) for the year ended December 31, 2020 were legally outstanding shares, including shares issued in exchange for related-party promissory notes. During 2020, the Company repurchased 85,594 of unvested shares of Hims Class A common stock for a cash payment of less than $0.1 million, which resulted in a reduction of deposit liability from the early exercise of stock options. In addition, in May 2020, an executive officer departed the Company, which resulted in the repurchase of 509,602 unvested shares of Hims Class A common stock in exchange for the cancellation of the principal payable of $0.9 million under an associated promissory note. Pre-Closing On January 20, 2021, the Company repurchased from its stockholders and cancelled 2,207,580 shares of Hims Class A common stock, including certain stockholders who exercised outstanding stock options, for aggregate payment of $22.0 million. Included within the shares repurchased was 183,548 shares of Hims Class A common stock from the net exercise of stock options as part of the pre-closing paid-in Merger Transaction Immediately prior to the Merger, each outstanding share of Hims’ Class F common stock and preferred stock converted into Hims Class A common stock at the then-effective conversion rate. As a result of the Merger, each outstanding share of the Hims capital stock was converted into the right to receive newly issued shares of the Company’s Class A common stock and certain other securities, other than the shares of Hims Class V common stock issued to its CEO immediately prior to the Closing, which were converted into the right to receive newly issued shares of the Company’s Class V common stock and certain other securities. On the Closing Date, each Hims stockholder received approximately 0.4530 shares of the Company’s Class A common stock, par value $0.0001 per share, for each share of Hims Class A common stock, par value $0.000001 per share, that such stockholder owned (with the CEO receiving 0.4530 shares of the Company’s Class V common stock, par value $0.0001 per share, for each share of Hims Class V common stock, par value $0.000001 per share, that the CEO owned). Each stockholder also received 0.0028 warrants exercisable for the Company’s Class A common stock, for each share of Hims Class A or Class V common stock owned by such stockholder prior to the Merger and earn-out Settlement of Nonrecourse Related-Party Promissory Notes In connection with the Merger, the obligations due under all nonrecourse related-party promissory notes were satisfied through the payment of $1.2 million and the forfeiture of 370,734 shares of the Company’s Class A common stock. PIPE Investment Concurrently with the execution of the Merger Agreement, certain investors collectively subscribed for 7,500,000 shares of the Company’s Class A common stock at $10.00 per share for aggregate gross proceeds of $75.0 million. Class A Common Stock Warrants As discussed above, Class A common stock warrants have been issued in connection with debt agreements (Note 10 – Borrowing Arrangements), vendor service agreements (Note 12 – Stock-Based Compensation), issuance of preferred stock (Note 13 – Redeemable Convertible Preferred Stock) and to all common stockholders and warrant holders as part of the Merger. Prior to Merger In July 2020, Hims Class A common stock warrants were exercised to purchase 143,452 shares of Hims Class A common stock at an exercise price of $0.06 per share. In November 2020, Hims Class A common stock warrants were exercised to purchase 425,146 and 37,244 shares of Hims Class A common stock at an exercise price of $0.06 and $1.75 per share, respectively. In December 2020, Class A common stock warrants were exercised to purchase 178,840 and 266,522 shares of Hims Class A common stock at an exercise price of $0.06 and $1.75 per share, respectively. On January 4, 2021, holders of Hims Class A common stock vendor warrants exercised their warrants and purchased 380,746 shares of Hims Class A common stock at an exercise price of $1.75 per share. Subsequent to Merger As the accounting acquirer, Hims was deemed to assume 3,012,500 Class A common stock warrants that were held by Oaktree Acquisition Holdings, L.P. (“Sponsor”) at an exercise price of $11.50 (“Private Placement Warrants”) and 6,708,333 Class A common stock warrants held by OAC’s shareholders at an exercise price of $11.50 (“Public Warrants”) as well as 888,143 Class A common stock warrants that were granted to Hims’ equity holders as part of the Merger. Subsequent to the Merger, the Private Placement Warrants, Public Warrants, and Parent Warrants for shares of Class A common stock meet liability classification requirements since the warrants may be required to be settled in cash under a tender offer. In addition, Private Placement Warrants are potentially subject to a different settlement amount as a result of being held by the Sponsor which precludes the Private Placement Warrants from being considered indexed to the entity’s own stock. Therefore, these warrants are classified as liabilities on the condensed consolidated balance sheets. Each warrant held by Hims’ stockholders that was unexercised at the time of the Merger was assumed by the Company and represents the right to receive (a) an equivalent warrant at an exchange ratio of 0.4530 (which was determined not to result in incremental expense); (b) the right to receive, upon exercise, earn-out 20-trading earn-out earn-out Distinguishing Liabilities from Equity In February 2021, all of the outstanding 3,012,500 Private Placement Warrants were net exercised for 1,474,145 shares of Class A common stock. As of March 31, 2021, the Company had the following warrants outstanding to purchase shares of Class A common stock (in thousands, except for share and per share amounts): Warrant Type Shares Exercise Price Issued Expiration Vendor 462,335 $ 1.75 September 23, 2019 September 23, 2026 Debt 98,723 6.96 March 12, 2020 November 26, 2026 Public 6,695,915 11.50 July 22, 2019 January 20, 2026 Parent 888,143 11.50 July 22, 2019 January 20, 2026 Public Warrants Terms The Public Warrants became exercisable into shares of Class A common stock upon 30 days after the Closing Date. The Public Warrants will expire at the later of five years after the completion of a business combination or upon redemption or liquidation. Commencing 90 days after the Public Warrants become exercisable, the Company may redeem all and only all of the Public Warrants: • at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined based on the redemption date at a price equal to the average last reported sale price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants; • if the last reported closing price of the Class A common stock equals or exceeds $10.00 per share (as adjusted per share splits, share dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders; • if there is an effective registration statement covering the Class A common stock issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day In addition, the Company may redeem all and only all of the Public Warrants for cash: • at a price of $0.01 per warrant; • upon a minimum of 30 days’ prior written notice of redemption; and • if the last reported closing price of the Class A common stock equals or exceeds $18.00 per share (as adjusted per share splits, share dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis, as described in the warrant agreement. Additionally, in no event will the Company be required to net cash settle.	Note 6—Shareholders’ Equity Class A Ordinary Shares Class B Ordinary Shares Holders of the Class A ordinary shares and holders of the Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders, except as required by law or stock exchange rule; provided that only holders of the Class B ordinary shares have the right to vote on the election of the Company’s directors prior to the initial Business Combination. The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the Preference Shares Warrants The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. The Private Placement Warrants are identical to the Public Warrants included in the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be non-redeemable Commencing 90 days after the Public Warrants become exercisable, the Company may redeem the Public Warrants: • in whole and not in part; • at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined based on the redemption date and the “fair market value” of the Class A ordinary shares (the “fair market value” of the Class A ordinary shares shall mean the average last reported sale price of the Class A ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants); • if, and only if, the last reported sale price of the Class A ordinary shares equals or exceeds $10.00 per share (as adjusted per share splits, share dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders; • if, and only if, the Private Placement Warrants are also concurrently exchanged at the same price (equal to a number of Class A ordinary shares) as the outstanding Public Warrants, as described above; and • if, and only if, there is an effective registration statement covering the Class A ordinary shares issuable upon exercise of the warrants (or such other security as the warrants may be exercisable for at the time of redemption) and a current prospectus relating thereto available throughout the 30-day period after written notice In addition, the Company may redeem the Public Warrants for cash (except with respect to the Private Placement Warrants): • in whole and not in part; • at a price of $0.01 per warrant; • upon a minimum of 30 days’ prior written notice of redemption; and • if, and only if, the last reported closing price of the Class A ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. Additionally, in no event will the Company be required to net cash settle any Warrants. If the Company is unable to complete the initial Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	15. Related-Party Transactions Atomic Labs, LLC (“Atomic Labs”) is a related-party venture capital startup studio that launched the Company, providing initial capital and governance. During the initial years of operation, the Company utilized operational support from Atomic Labs, primarily consisting of providing office space, conducting back-office professional services, and administering operating expenses. Additionally, an affiliated company of Atomic Labs provides professional services to the Company, primarily to support engineering and operations functions. All services were provided at cost. For both the three months ended March 31, 2021 and 2020, the Company recorded a total of $0.8 million to Atomic Labs and its affiliated company for services performed and costs incurred on behalf of the Company. There was no accounts payable balance owed to Atomic Labs and its affiliated company as of March 31, 2021 or December 31, 2020. In addition, for the three months ended March 31, 2021 and 2020, the Company recorded $0.1 million and less than $0.1 million for payments made to Vouched, a related-party company that provides identity verification services. These expenses were recognized as selling, general, and administrative expenses. There was $0.1 million and less than $0.1 million of payables owed to Vouched as of March 31, 2021 and December 31, 2020. Nonrecourse Related-Party Promissory Notes As of December 31, 2020, the Company had promissory notes from certain of the Company’s executive officers, as well as a founding employee and an executive chairman. The promissory notes, which were issued to the Company by the related parties as consideration for the exercise of stock options, are considered nonrecourse notes for accounting purposes. The loans are secured by the shares of Hims Class A common stock held by the individuals. There were 16,345,627 shares of Hims Class A common stock securing the related-party promissory notes as of December 31, 2020. The related-party promissory notes bore interest between 2.21% and 3.02% per annum. The loans were due upon the earliest of (1) ten years from the debt issuance date, (2) a liquidation of the Company, or (3) six months following an initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended. Prepayment of principal and interest may be made at any time without penalty. The nonrecourse related-party promissory notes are not given accounting effect until the notes are repaid in full as the underlying stock options are not considered exercised for accounting purposes. As of December 31, 2020, the total outstanding balance under these promissory notes was $7.2 million. In connection with the Merger, the obligations due under all nonrecourse related-party promissory notes were satisfied through the payment of $1.2 million and the forfeiture of 370,734 shares of Hims Class A common stock. The related-party promissory notes were settled within additional paid-in Redeemable Common Stock Transaction On September 23, 2019, the Company’s CEO and a member of its Board of Directors, sold 737,058 shares of Hims Class A common stock to third party purchasers at $6.11 per share for aggregate consideration of $4.5 million pursuant to Hims Class A Common Stock Purchase Agreements. Under the terms of the vendor service agreement with the third party, the purchasers were granted a put right entitling them to sell the shares to the Company at $6.11 per share for a period of six months. The put right expired on March 23, 2020 without the purchasers exercising their rights to sell the shares to the Company. The Company recorded stock-based compensation expense associated with the transaction of $3.0 million. Upon expiration of the redemption right, the Company reclassified the aggregate consideration of $4.5 million that was subject to redemption from mezzanine equity to stockholders’ equity on the condensed consolidated balance sheet as of March 31, 2020.	Note 4—Related Party Transactions Founder Shares In April 2019, the Sponsor paid $25,000 to cover certain offering costs of the Company in consideration of 4,312,500 Class B ordinary shares, par value $0.0001, (the “Founder Shares”). On June 26, 2019, the Company effected a pro rata share capitalization resulting in an increase in the total number of Class B ordinary shares outstanding from 4,312,500 to 5,031,250. All share amounts have been retroactively restated to reflect the share capitalization. The Sponsor had agreed to forfeit up to 656,250 Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriters. The forfeiture would have been adjusted to the extent that the over-allotment option was not exercised in full by the underwriters so that the Founder Shares would have represented 20% of the Company’s issued and outstanding shares after the Initial Public Offering. The underwriters exercised their over-allotment option in full on July 22, 2019; thus, the Founder Shares are no longer subject to forfeiture. The initial shareholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at Private Placement Warrants Concurrently with the closing of the Initial Public Offering, on July 22, 2019 the Company sold 4,016,667 Private Placement Warrants at a price of $1.50 per Private Placement Warrant to the Sponsor, generating gross proceeds of approximately $6.03 million. Each whole Private Placement Warrant is exercisable for one Class A ordinary share at a price of $11.50 per share. Certain of the proceeds from the sale of the Private Placement Warrants were added to the net proceeds from the Initial Public Offering and are held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants are non-redeemable and exercisable on a The Sponsor and the Company’s officers and directors have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination is not consummated within the Combination Period, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. To date, the Company had no borrowings under any Working Capital Loan. Expense Reimbursements Prior to the closing of the Initial Public Offering, the Sponsor agreed, pursuant to an expense reimbursement agreement (the “Expense Reimbursement Agreement”), to advance the Company up to $300,000 to pay for a portion of the expenses incurred in connection with the Initial Public Offering. The Sponsor advanced approximately $62,000 to the Company under the Expense Reimbursement Agreement. The Company repaid this advance in full on November 18, 2019. Administrative Support Agreement Commencing on the effective date of the Initial Public Offering, the Company agreed to pay an affiliate of the Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. Upon completion of an initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company incurred approximately $120,000 and $55,000 for the year ended December 31, 2020 and during the period from April 9, 2019 (inception) through December 31, 2019, respectively, in expenses in connection with such services as reflected in the accompanying statement of operations. As of December 31, 2020 and December 31, 2019, the Company had approximately $60,000 and $55,000, respectively, in accrued expenses for related party in connection with such services as reflected in the accompanying balance sheets. During the year ended December 31, 2020, the Company paid approximately $115,000 of the outstanding accrued administrative support fees.

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	16. Basic and Diluted Net Loss per Share Prior to the Merger and prior to effecting the recapitalization, the Company had two classes of common stock: Hims Class A and Hims Class F common stock. The rights of the holders of Hims Class A and Hims Class F common stock were identical, including the liquidation and dividend rights, except with respect to electing members of the Board of Directors and voting rights. As the liquidation and dividend rights were identical, undistributed earnings and losses were allocated on a proportionate basis and the resulting net loss per share attributable to common stockholders was the same for both Hims Class A and Hims Class F common stock on an individual and combined basis. Subsequent to the Merger, the Company continues to have two classes of common stock: Class A and Class V common stock. Similar to the previous structure, the rights are identical, including liquidation and dividend rights, except Class V common stock has additional voting rights. The Company uses the two-class The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three months ended March 31 (in thousands, except share and per share amounts): 2021 2020 Class A Class V Class A Class F Numerator: Net loss attributable to common stockholders $ (49,185 ) $ (2,219 ) $ (4,823 ) $ (1,210 ) Denominator: Weighted average shares outstanding, basic and diluted 146,471,524 6,609,014 27,668,709 6,941,352 Basic and diluted net loss per share $ (0.34 ) $ (0.34 ) $ (0.17 ) $ (0.17 ) Basic and diluted net loss per share attributable to common stockholders is the same for the three months ended March 31, 2021 and 2020, because the inclusion of potential shares of common stock would have been anti-dilutive for the periods presented. There were no redeemable shares during the three months ended March 31, 2021. During the three months ended March 31, 2020, weighted average Hims Class A common shares presented excludes 664,162 shares subject to redemption. These shares do not absorb losses. The following table discloses securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share: Three Months Ended March 31, 2021 2020 Common stock issued for exercise of stock options subject to nonrecourse promissory notes 3,545,821 16,855,230 Common stock issued for early exercise of stock options 388,839 154,820 Redeemable convertible preferred stock 19,702,603 85,510,700 Stock options 16,361,955 6,969,701 RSUs 3,347,300 — Warrants to purchase Class A common stock 7,733,346 1,895,345 Warrants to purchase redeemable convertible preferred stock — 1,433,585

Income Tax

Income Tax	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Tax	17. Income Tax Our effective income tax rate was -0.2% -0.6%

Initial Public Offering

Initial Public Offering	12 Months Ended
	Dec. 31, 2020
Initial Public Offering [Abstract]
Initial Public Offering	Note 3—Initial Public Offering On July 22, 2019, the Company sold 20,125,000 Units, including 2,625,000 Over-Allotment Units, at a price of $10.00 per Unit, generating gross proceeds of $201.25 million, and incurring offering costs of approximately $11.9 million, inclusive of approximately $7.04 million in deferred underwriting commissions (see Note 5). Each Unit consists of one Class A ordinary share and one-third of one redeemable warrant per share, subject to adjustment (see Note 6).

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 8—Subsequent Events Management has evaluated subsequent events to determine if events or transactions occurring through the date the financial statements were available for issuance require potential adjustment to or disclosure in the financial statements and has concluded that all such events that would require recognition or disclosure have been recognized or disclosed. On January 20, 2021, the Company completed the Merger pursuant to the Merger Agreement as described in Note 1. As contemplated by the Merger Agreement and as described in the Company’s definitive proxy statement filed with the SEC on December 29, 2020 (the “Proxy Statement”), (i) the Company became a Delaware corporation and, in connection with the Domestication, (A) the Company’s name changed to “Hims & Hers Health, Inc.”, (B) each outstanding Class A ordinary share of the Company and each outstanding Class B ordinary share of the Company became one share of Class A common stock of the Company, and (C) each outstanding warrant of the Company became one warrant to purchase one share of New Hims Class A Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Hims, with Hims as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of the Company. In February 2021, the Company net exercised 3,012,500 warrants for 1,474,145 shares of New Hims Class A Common Stock.

Restatement of Previously Issue

Restatement of Previously Issued Audited and Unaudited Financial Statements	12 Months Ended
	Dec. 31, 2020
Restatement [Abstract]
Restatement of Previously Issued Audited and Unaudited Financial Statements	Note 9—Restatement of Previously Issued Audited and Unaudited Financial Statements In May 2021, the Audit Committee of the Company’s board of directors, after considering the recommendations of management, concluded that, because of a misapplication of the accounting guidance related to its Warrants, the Company’s previously issued financial statements for the periods beginning April 9, 2019 (inception) through December 31, 2020 (collectively, the “Affected Periods”) should no longer be relied upon. As such, the Company is restating its financial statements for the Affected Periods. On April 12, 2021, the Staff of the SEC issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “Staff Statement”). In the Staff Statement, the Staff of the SEC expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance on July 22, 2019, the Company’s Warrants were accounted for as equity within the Company’s previously reported balance sheets. Accordingly, the statements of operations did not include any subsequent noncash changes in estimated fair value of the Warrants. The views expressed in the Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement. In light of the Staff Statement, the Company reassessed its accounting for the Warrants. Based on this reassessment, and after discussion and evaluation with the Company’s independent registered public accounting firm and the Audit Committee, management concluded that the Warrants should be presented as liabilities with subsequent fair value remeasurement. The warrant agreement governing the Warrants includes a provision (the “Replacement of Securities Upon Reorganization”), the application of which could result in a different settlement value for the Warrants depending on their holder. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed The following presents a reconciliation of the balance sheets, statements of operations and cash flows for the Affected Periods. The restatement had no impact on net cash flows from operating, investing or financing activities. December 31, 2020 balance sheet: As of December 31, 2020 As Previously Restatement As Restated Total assets $ 205,633,422 $ — $ 205,633,422 Liabilities and Shareholders’ Equity Total current liabilities $ 4,896,647 $ — $ 4,896,647 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 47,571,334 47,571,334 Total liabilities 12,090,397 47,571,334 59,661,731 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 188,543,020 (47,571,330 ) 140,971,690 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 127 477 604 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 6,901,127 33,369,400 40,270,527 Accumulated deficit (1,901,752 ) (33,369,881 ) (35,271,633 ) Total shareholders’ equity 5,000,005 (4 ) 5,000,001 Total liabilities and shareholders’ equity $ 205,633,422 $ — $ 205,633,422 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of December 31, 2020 As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 18,854,302 (4,757,133 ) 14,097,169 Ordinary shares—shares issued and outstanding 1,270,698 4,757,133 6,027,831 Year ended December 31, 2020 statement of operations: Year Ended December 31, 2020 As Previously Restatement As Restated General and administrative expenses $ 4,791,727 $ — $ 4,791,727 Loss from operations (4,791,727 ) — (4,791,727 ) Change in fair value of warrant liability — (37,221,917 ) (37,221,917 ) Gain on investments (net), dividends and interest, held in Trust Account 1,742,713 — 1,742,713 Net loss $ (3,049,014 ) $ (37,221,917 ) $ (40,270,931 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.07 $ — $ 0.07 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.89 ) $ — $ (8.29 ) Year ended December 31, 2020 statement of cash flows: Year Ended December 31, 2020 As Previously Restatement As Restated Net loss $ (3,049,014 ) $ (37,221,917 ) $ (40,270,931 ) Adjustments to reconcile net loss to net cash used in operating activities (1,742,713 ) 37,221,917 35,479,204 Net cash used in operating activities (777,074 ) — (777,074 ) Net cash provided by investing activities 325,000 — 325,000 Net cash provided by (used in) financing activities — — — Net change in cash $ (452,074 ) $ $ (452,074 ) Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ (3,049,010 ) $ (37,221,920 ) $ (40,270,930 ) September 30, 2020 balance sheet: As of September 30, 2020 (Unaudited) As Previously Restatement As Restated Total assets $ 205,813,988 $ — $ 205,813,988 Liabilities and Shareholders’ Equity Total current liabilities $ 3,037,725 $ — $ 3,037,725 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 31,902,349 31,902,349 Total liabilities 10,231,475 31,902,349 42,133,824 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 190,582,510 (31,902,350 ) 158,680,160 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 107 320 427 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 4,861,657 17,700,577 22,562,234 Accumulated deficit 137,736 (17,700,896 ) (17,563,160 ) Total shareholders’ equity 5,000,003 1 5,000,004 Total liabilities and shareholders’ equity $ 205,813,988 $ — $ 205,813,988 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of September 30, 2020 (Unaudited) As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,058,251 (3,190,235 ) 15,868,016 Ordinary shares - shares issued and outstanding 1,066,749 3,190,235 4,256,984 Three months ended September 30, 2020 statement of operations: Three Months Ended September 30, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 2,338,004 $ — $ 2,338,004 Loss from operations (2,338,004 ) — (2,338,004 ) Change in fair value of warrant liability — (17,522,107 ) (17,522,107 ) Gain on investments (net), dividends and interest, held in Trust Account 81,232 — 81,232 Net loss $ (2,256,772 ) $ (17,522,107 ) $ (19,778,879 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ — $ — $ — Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.46 ) $ — $ (3.95 ) Nine months ended September 30, 2020 statement of operations: Nine Months Ended September 30, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 2,708,421 $ — $ 2,708,421 Loss from operations (2,708,421 ) — (2,708,421 ) Change in fair value of warrant liability — (21,552,932 ) (21,552,932 ) Gain on investments (net), dividends and interest, held in Trust Account 1,698,895 — 1,698,895 Net loss $ (1,009,526 ) $ (21,552,932 ) $ (22,562,458 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.08 $ — $ 0.08 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.54 ) $ — $ (4.82 ) Nine months ended September 30, 2020 statement of cash flows: Nine Months Ended September 30, 2020 (Unaudited) As Previously Restatement As Restated Net loss $ (1,009,526 ) $ (21,552,932 ) $ (22,562,458 ) Adjustments to reconcile loss to net cash used in operating activities (1,698,895 ) 21,552,932 19,854,037 Net cash used in operating activities (577,740 ) — (577,740 ) Net cash provided by investing activities 325,000 — 325,000 Net cash provided by (used in) financing activities — — — Net change in cash $ (252,740 ) $ — $ (252,740 ) Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ (1,009,520 ) $ (21,552,940 ) $ (22,562,460 ) June 30, 2020 balance sheet: As of June 30, 2020 (Unaudited) As Previously Restatement As Restated Total assets $ 206,200,737 $ — $ 206,200,737 Liabilities and Shareholders’ Equity Total current liabilities $ 1,167,702 $ — $ 1,167,702 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 14,380,242 14,380,242 Total liabilities 8,361,452 14,380,242 22,741,694 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 192,839,280 (14,380,240 ) 178,459,040 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 84 145 229 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 2,604,910 178,642 2,783,552 Retained earnings 2,394,508 (178,789 ) 2,215,719 Total shareholders’ equity 5,000,005 (2 ) 5,000,003 Total liabilities and shareholders’ equity $ 206,200,737 $ — $ 206,200,737 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of June 30, 2020 (Unaudited) As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,283,928 (1,438,024 ) 17,845,904 Ordinary shares - shares issued and outstanding 841,072 1,438,024 2,279,096 Three months ended June 30, 2020 statement of operations: Three Months Ended June 30, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 123,634 $ — $ 123,634 Loss from operations (123,634 ) — (123,634 ) Change in fair value of warrant liability — (3,050,354 ) (3,050,354 ) Gain on investments (net), dividends and interest, held in Trust Account 36,858 — 36,858 Net loss $ (86,776 ) $ (3,050,354 ) $ (3,137,130 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.00 $ — $ 0.00 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.02 ) $ — $ (0.63 ) Six months ended June 30, 2020 statement of operations: Six Months Ended June 30, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 370,417 $ — $ 370,417 Loss from operations (370,417 ) — (370,417 ) Change in fair value of warrant liability — (4,030,825 ) (4,030,825 ) Gain on investments (net), dividends and interest, held in Trust Account 1,617,663 — 1,617,663 Net income (loss) $ 1,247,246 $ (4,030,825 ) $ (2,783,579 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.08 $ — $ 0.08 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.07 ) $ — $ (0.87 ) Six months ended June 30, 2020 statement of cash flows: Six Months Ended June 30, 2020 (Unaudited) As Previously Restatement As Restated Net income (loss) $ 1,247,246 $ (4,030,825 ) $ (2,783,579 ) Adjustments to reconcile net income (loss) to net cash used in operating activities (1,617,663 ) 4,030,825 2,413,162 Net cash used in operating activities (124,809 ) — (124,809 ) Net cash provided by (used in) investing activities — — — Net cash provided by (used in) financing activities — — — Net change in cash $ (124,809 ) $ — $ (124,809 ) Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ 1,247,250 (4,030,830 ) (2,783,580 ) March 31, 2020 balance sheet: As of March 31, 2020 (Unaudited) As Previously Restatement As Restated Total assets $ 206,287,199 $ — $ 206,287,199 Liabilities and Shareholders’ Equity Total current liabilities $ 1,167,388 $ — $ 1,167,388 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 11,329,888 11,329,888 Total liabilities 8,361,138 11,329,888 19,691,026 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 192,926,060 (11,329,890 ) 181,596,170 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 83 114 197 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 2,518,131 (2,871,677 ) (353,546 ) Retained earnings 2,481,284 2,871,565 5,352,849 Total shareholders’ equity 5,000,001 2 5,000,003 Total liabilities and shareholders’ equity $ 206,287,199 $ — $ 206,287,199 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of March 31, 2020 (Unaudited) As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,292,606 (1,132,989 ) 18,159,617 Ordinary shares - shares issued and outstanding 832,394 1,132,989 1,965,383 Three months ended March 31, 2020 statement of operations: Three Months Ended March 31, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 246,783 $ — $ 246,783 Loss from operations (246,783 ) — (246,783 ) Change in fair value of warrant liability — (980,471 ) (980,471 ) Gain on investments (net), dividends and interest, held in Trust Account 1,580,805 — 1,580,805 Net income $ 1,334,022 $ (980,471 ) $ 353,551 Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.08 $ — $ 0.08 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.05 ) $ — $ (0.24 ) Three months ended March 31, 2020 statement of cash flows: Three Months Ended March 31, 2020 (Unaudited) As Previously Restatement As Restated Net income $ 1,334,022 $ (980,471 ) $ 353,551 Adjustments to reconcile net income to net cash used in operating activities (1,580,805 ) 980,471 (600,334 ) Net cash used in operating activities (28,639 ) — (28,639 ) Net cash provided by (used in) investing activities — — — Net cash provided by (used in) financing activities — — — Net change in cash $ (28,639 ) $ — $ (28,639 ) Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ 1,334,030 $ (980,480 ) $ 353,550 December 31, 2019 balance sheet: As of December 31, 2019 As Previously Restatement As Restated Total assets $ 204,765,183 $ — $ 204,765,183 Liabilities and Shareholders’ Equity Total current liabilities $ 979,394 $ — $ 979,394 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 10,349,417 10,349,417 Total liabilities 8,173,144 10,349,417 18,522,561 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 191,592,030 (10,349,410 ) 181,242,620 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 97 104 201 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 3,852,147 (3,852,147 ) — Retained earnings 1,147,262 3,852,036 4,999,298 Total shareholders’ equity 5,000,009 (7 ) 5,000,002 Total liabilities and shareholders’ equity $ 204,765,183 $ — $ 204,765,183 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of December 31, 2019 As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,159,203 (1,034,941 ) 18,124,262 Ordinary shares - shares issued and outstanding 965,797 1,034,941 2,000,738 Period from April 9, 2019 (inception) to December 31, 2019 statement of operations: Period from April 9, 2019 (inception) to December 31, 2019 As Previously Restatement As Restated General and administrative expenses $ 710,080 $ 600,675 $ 1,310,755 Loss from operations (710,080 ) (600,675 ) (1,310,755 ) Change in fair value of warrant liability — 5,503,291 5,503,291 Gain on investments (net), dividends and interest, held in Trust Account 1,857,342 — 1,857,342 Net income $ 1,147,262 $ 4,902,616 $ 6,049,878 Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.08 $ — $ 0.08 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.08 ) $ — $ 0.90 Period from April 9, 2019 (inception) to December 31, 2019 statement of cash flows: Period from April 9, 2019 (inception) To December 31, 2019 As Previously Restatement As Restated Net income $ 1,147,262 $ 4,902,616 $ 6,049,878 Adjustments to reconcile net income to net cash used in operating activities (1,857,342 ) (4,902,616 ) (6,759,958 ) Net cash used in operating activities (241,682 ) — (241,682 ) Net cash used in investing activities (201,250,000 ) — (201,250,000 ) Net cash provided by financing activities 203,002,023 — 203,002,023 Net change in cash $ 1,510,341 $ — $ 1,510,341 Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ 191,592,030 $ (10,349,410 ) $ 181,242,620 Initial fair value of warrant liability — (15,852,708 ) (15,852,708 ) September 30, 2019 balance sheet: As of September 30, 2019 (Unaudited) As Previously Restatement As Restated Total assets $ 204,094,833 $ — $ 204,094,833 Liabilities and Shareholders’ Equity Total current liabilities $ 1,036,867 $ — $ 1,036,867 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 10,840,587 10,840,587 Total liabilities 8,230,617 10,840,587 19,071,204 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 190,864,210 (10,840,590 ) 180,023,620 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 104 109 213 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 4,579,960 (4,411,552 ) 168,408 Retained earnings 419,439 4,411,446 4,830,885 Total shareholders’ equity 5,000,006 3 5,000,009 Total liabilities and shareholders’ equity $ 204,094,833 $ — $ 204,094,833 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of September 30, 2019 (Unaudited) As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,086,421 (1,084,059 ) 18,002,362 Ordinary shares - shares issued and outstanding 1,038,579 1,084,059 2,122,638 Three months ended September 30, 2019 statement of operations: Three Months Ended September 30, 2019 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 449,938 $ 600,675 $ 1,050,613 Loss from operations (449,938 ) (600,675 ) (1,050,613 ) Change in fair value of warrant liability — 5,012,121 5,012,121 Gain on investments (net), dividends and interest, held in Trust Account 885,983 — 885,983 Net income $ 436,045 $ 4,411,446 $ 4,847,491 Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.04 $ — $ 0.04 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.09 ) $ — $ 0.79 Period from April 9, 2019 (inception) to September 30, 2019 statement of operations: Period from April 9, 2019 (inception) to September 30, 2019 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 466,544 $ 600,675 $ 1,067,219 Loss from operations (466,544 ) (600,675 ) (1,067,219 ) Change in fair value of warrant liability — 5,012,121 5,012,121 Gain on investments (net), dividends and interest, held in Trust Account 885,983 — 885,983 Net income $ 419,439 $ 4,411,446 $ 4,830,885 Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.04 $ — $ 0.04 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.09 ) $ — $ 0.79 Period from April 9, 2019 (inception) to September 30, 2019 statement of cash flows: Period from April 9, 2019 (inception) To September 30, 2019 (Unaudited) As Previously Restatement As Restated Net income $ 419,439 $ 4,411,446 $ 4,830,885 Adjustments to reconcile net income to net cash used in operating activities (885,983 ) (4,411,446 ) (5,297,429 ) Net cash used in operating activities (207,200 ) — (207,200 ) Net cash used in investing activities (201,250,000 ) — (201,250,000 ) Net cash provided by financing activities 203,238,700 — 203,238,700 Net change in cash $ 1,781,500 $ — $ 1,781,500 Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ 190,864,210 $ (10,840,590 ) $ 180,023,620 Initial fair value of warrant liability — (15,852,708 ) (15,852,708 )

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Concentration of Credit Risk			Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Cash and Cash Equivalents			Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had approximately $24 and $17,000 in cash equivalents held in the Trust Account as of December 31, 2020 and 2019, respectively.
Marketable Securities Held in Trust Account			Marketable Securities Held in Trust Account The Company’s portfolio of marketable securities is comprised solely of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in gain on marketable securities (net), dividends and interest, held in the Trust Account in the accompanying statement of operations. The estimated fair values of marketable securities held in the Trust Account are determined using available market information.
Fair Value of Financial Instruments			Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of December 31, 2020 and 2019, the carrying values of cash, accounts payable, accrued expenses, and advances from related party approximate their fair values due to the short-term nature of the instruments. The Company’s portfolio of marketable securities held in the Trust Account is comprised mainly of investments in U.S. Treasury securities with an original maturity of 185 days or less. The fair value for trading securities is determined using quoted market prices in active markets.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements as of March 31, 2021 are unaudited. The condensed consolidated balance sheet as of December 31, 2020, included herein was derived from the audited consolidated financial statements as of that date. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the year ended December 31, 2020 (the “audited consolidated financial statements”). The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and reflect, in management’s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s balance sheet, results of operations, and cash flows for the three-month periods, but are not necessarily indicative of the results expected for the full fiscal year or any other period.
Consolidation	The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany transactions and balances have been eliminated in these condensed consolidated financial statements.
Use of Estimates	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation and recognition of warrants, and estimates in capitalization of website development and internal-use		The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future conforming events. Accordingly, the actual results could differ from those estimates.
Offering Costs Associated with the Initial Public Offering			Offering Costs Associated with the Initial Public Offering Offering costs consist of legal, accounting, underwriting fees and other costs incurred that are directly related to the Initial Public Offering. Offering costs related to the issuance of shares were recognized in shareholders’ equity while costs associated with the warrant liabilities were charged to expense upon the completion of the Initial Public Offering on July 22, 2019.
Class A Ordinary Shares Subject to Possible Redemption			Class A Ordinary Shares Subject to Possible Redemption Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020 and 2019, 14,097,169 and 18,124,262, respectively, Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheets.
Net Income Per Ordinary Share			Net Income Per Ordinary Share Net income per share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of 10,725,000 of the Company’s Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method. The Company’s statement of operations includes a presentation of income per share for ordinary shares subject to redemption in a manner similar to the two-class method Net income per ordinary share, basic and diluted for Class A ordinary shares are calculated by dividing the interest income earned on investments and marketable securities held in the Trust Account of approximately $1.7 million, net of $325,000 annual limit of Regulatory Withdrawal available to be withdrawn from the Trust Account, resulting in a total of approximately $1.4 million for the year ended December 31, 2020, by the weighted average number of Class A ordinary shares outstanding for the period. Net loss per ordinary share, basic and diluted for Class B ordinary shares is calculated by dividing the net loss of approximately $40.3 million, less income attributable to Class A ordinary shares of approximately $1.4 million, resulted in a net loss of approximately $41.7 million, by the weighted average number of Class B ordinary shares outstanding for the period. Net income per ordinary share, basic and diluted for Class A ordinary shares are calculated by dividing the interest income earned on investments and marketable securities held in the Trust Account of approximately $1.9 million, net of $325,000 annual limit of Regulatory Withdrawal available to be withdrawn from the Trust Account, resulting in a total of approximately $1.5 million for the period from April 9, 2019 (inception) through December 31, 20 19 in a net loss of approximately $4.5 million
Warrant Liability			Warrant Liability The Company accounts for warrants for shares of the Company’s Class A ordinary shares as liabilities held at fair value on the balance sheet. The warrants are subject to remeasurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense), net on the statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants. At that time, the warrant liability will be reclassified to additional paid-in
Income Taxes			Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740, Simplifying the Accounting for Income Taxes, prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020 and 2019. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2020 and 2019. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Investments		Investments Available-for-sale Available-for-sale The investments, if any, are designated as available-for-sale
Other-Than-Temporary Impairment	Other-Than-Temporary Impairment The Company’s investments are subject to a periodic impairment review. Investments are considered impaired when the fair value is below the investment’s adjusted cost basis. This would occur for marketable debt instruments when the fair value is below amortized cost and the Company intends to sell the instrument, when it is more likely than not that the Company will be required to sell the instrument before recovery of its amortized cost basis, or when the Company does not expect to recover the entire amortized cost basis of the instrument (a credit loss exists). When the Company does not expect to recover the entire amortized cost basis of the instrument, it separates other-than-temporary impairments into amounts representing credit losses, which are recognized in other (expense) income, net, and amounts related to all other factors, which are recognized in other comprehensive (loss) income on the condensed consolidated statements of operations and comprehensive loss. The Company incurred no other-than-temporary impairments on investments for the three months ended March 31, 2021 or 2020.
Inventory	Inventory Inventory primarily consists of finished goods and raw materials that are located at Company-managed and third-party fulfillment warehouses. Inventory is stated at the lower of cost and net realizable value and inventory cost is determined by the weighted average cost method. The Company reserves for expired, slow-moving, and excess inventory by estimating the net realizable value based on the potential future use of such inventory. Management monitors inventory to identify events that would require impairment due to slow-moving, expired, or obsolete inventory and reduces the value of inventory when required. Obsolete inventory balances are written off against the inventory allowance when management determines that the inventory cannot be sold. The Company recorded write-offs of less than $0.1 million for the three months ended March 31, 2021 and $0.1 million for the three months ended March 31, 2020.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification Topic (“ASC”) 606, Revenue from Contracts with Customers The Company’s consolidated revenue primarily comprises of online sales of health and wellness products through the Company’s website, including prescription and nonprescription products. In contracts that contain prescription products, revenue also includes medical consultation services. Additionally, starting in March 2020, the Company began selling its products to a new wholesale partner. Revenue consists of the following (in thousands): For the Three Months Ended March 31, 2021 2020 Online $ 50,680 $ 28,524 Wholesale 1,634 1,539 Total revenue $ 52,314 $ 30,063 For online revenue, the Company defines its customer as an individual who purchases products or services through the website. For wholesale revenue, Company defines its customer as a wholesale partner. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus margin-based estimates. For each of the three months ended March 31, 2021 and 2020, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups”, which are professional corporations or other professional entities owned by licensed physicians and other professional entities that engage licensed healthcare professionals (medical doctors, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 8 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services. Additionally, to fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with affiliated and third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) to fill prescriptions that are ordered by the Company’s customers. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, at its sole discretion, sets all listed prices charged on its website for products and services. The Company estimates refunds using the expected value method based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company has made an accounting policy election to account for shipping and handling activities performed after the control of a product has been transferred to the customer as fulfillment costs, with direct costs to ship products to customers included in cost of revenue. The Company’s contracts with customers do not contain costs to obtain or costs to fulfill contracts with customers in accordance with ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers For online sales, payment for prescription medication and nonprescription products is typically collected from the customer a few days in advance of product shipment. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the condensed consolidated balance sheets since the associated revenue will be primarily recognized within the following period. For wholesale arrangements, payments are collected in accordance with contract terms.
Stock-Based Compensation	Stock-Based Compensation The fair value of stock options, equity-classified warrants issued to vendors, and restricted stock units (“RSUs”), are measured at the grant date fair value. The fair value of employee stock options and vendor warrants are generally determined using the Black-Scholes Merton (“BSM”) option-pricing model using various inputs, including estimates of expected volatility, term, risk-free rate, and future dividends. Stock options that were granted to the Company’s Chief Executive Officer (“CEO”) with performance and market conditions and earn-out
Warrant Liabilities	Warrant Liabilities The Company classifies Private Placement Warrants and Public Warrants (both defined and discussed in Note 14 – Common Stock) as liabilities in addition to warrants to purchase preferred stock. At the end of each reporting period, changes in fair value during the period are recognized as a component of other (expense) income, net within the consolidated statements of operations and comprehensive loss. The Company will continue to adjust the warrant liability for changes in the fair value until the earlier of a) the exercise or expiration of the warrants or b) the redemption of the warrants, at which time the warrants will be reclassified to additional paid-in
Leases	Leases The Company currently leases a warehouse facility and previously leased office space under noncancelable lease agreements that are accounted for as operating leases. Rent expense is recorded on a straight-line basis over the lease term. For rent abatement and rent escalation provisions, the Company recognizes the related rent expense on a straight-line basis over the lease term. The difference between cash rent payments and the recognition of straight-line rent expense is recorded as deferred rent and amortized over the lease term.
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement Fair Value Measurement Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) right-of-use In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments available-for-sale 2018-19 2016-13 2019-04 2019-10 2019-11, 2020-02 2020-03, 2016-13. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes 2019-12 2019-12 In October 2020, the FASB issued ASU 2020-10, Codification Improvements 2020-10		Recent Accounting Pronouncements The Company’s management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Disaggregation of Revenue	Revenue consists of the following (in thousands): For the Three Months Ended March 31, 2021 2020 Online $ 50,680 $ 28,524 Wholesale 1,634 1,539 Total revenue $ 52,314 $ 30,063

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Short-term investments as of March 31, 2021, consist of the following (in thousands): Adjusted Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 177,273 $ 1 $ (53 ) $ 177,221 Government bonds 40,955 2 (5 ) 40,952 Asset-backed bonds 16,928 — (4 ) 16,924 Total short-term investments $ 235,156 $ 3 $ (62 ) $ 235,097 Short-term investments as of December 31, 2020, consist of the following (in thousands): Adjusted Cost Unrealized Gains Unrealized Fair Value Corporate bonds $ 55,224 $ 5 $ (2 ) $ 55,227 Government bonds 14,121 2 — 14,123 Asset-backed bonds 3,514 — — 3,514 Total short-term investments $ 72,859 $ 7 $ (2 ) $ 72,864

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventory consists of the following (in thousands): March 31, December 31, Finished goods $ 3,546 $ 2,856 Raw materials 977 687 Total inventory $ 4,523 $ 3,543

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure	Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, Trade and other receivables, net $ 942 $ 1,147 Prepaid expenses 8,650 2,691 Vendor deposits 2,810 1,395 Other current assets 5 171 Total prepaid expenses and other current assets $ 12,407 $ 5,404

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): March 31, December 31, Marketing expenses $ 1,514 $ 1,122 Professional services 1,480 1,241 Payroll costs 1,250 919 Tax payables 729 651 Warrant exercise deposit liability — 664 Other accrued liabilities 850 387 Total accrued liabilities $ 5,823 $ 4,984

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of fair value assets measured on recurring basis		The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and 2019 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. December 31, 2020: Description Quoted Prices in Significant Other Significant Other Assets held in Trust Account: U.S. Treasury Securities $ 204,525,031 $ — $ — Cash equivalents - money market funds 24 — — $ 204,525,055 $ — $ — Liabilities: Public Warrants $ 26,162,499 $ — $ — Private Placement Warrants — — 21,408,835 $ 26,162,499 $ — $ 21,408,835 December 31, 2019: Description Quoted Prices in Significant Other Significant Other Assets held in Trust Account: U.S. Treasury Securities $ 203,090,272 $ — $ — Cash equivalents - money market funds 17,070 — — $ 203,107,342 $ — $ — Liabilities: Public Warrants $ 6,372,917 $ — $ — Private Placement Warrants — — 3,976,500 $ 6,372,917 $ — $ 3,976,500
Summary of quantitative information regarding Level 3 fair value measurement inputs of Warrants	The following assumptions were used for the valuation of the Private Placement Warrants on the settlement date: Expected term 0.16 Volatility 65.00 % Risk-free rate 0.03 % Dividend yield — %	The following table provides quantitative information regarding Level 3 fair value measurement inputs: December 31, 2020 2019 Expected term 0.31 1.75 Volatility 55.00 % 29.60 % Risk-free rate 0.10 % 0.14 % Dividend yield 0.00 % 0.00 %
Summary of fair value of the warrant liabilities	The change in the fair value of warrant liabilities is as follows (in thousands): Balance at December 31, 2020 $ 906 Conversion of Series D preferred stock warrants to Class A common stock warrants (1,160 ) Private Placement Warrants and Public Warrants 51,814 Exercised warrants (20,871 ) Increase in fair value of warrants 2,681 Balance at March 31, 2021 $ 33,370	The change in the fair value of the warrant liabilities is summarized as follows: December 31, 2020 2019 Beginning balance $ 10,349,417 $ — Issuance of Public and Private Placement Warrants — 15,852,708 Change in fair value 37,221,917 (5,503,291 ) Ending balance $ 47,571,334 $ 10,349,417
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 74,930 $ — $ — $ 74,930 Government bonds — 11,082 — 11,082 Short-term investments: Corporate bonds — 177,221 — 177,221 Government bonds — 40,952 — 40,952 Asset-backed bonds — 16,924 — 16,924 Restricted cash: Money market funds 856 — — 856 Total assets 75,786 246,179 — 321,965 Liabilities Warrant liabilities 33,370 — — 33,370 Total liabilities $ 33,370 $ — $ — $ 33,370 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 12,163 $ — $ — $ 12,163 Government bonds — 12,693 — 12,693 Short-term investments: Corporate bonds — 55,227 — 55,227 Government bonds — 14,123 — 14,123 Asset-backed bonds — 3,514 — 3,514 Restricted cash: Money market funds 1,006 — — 1,006 Total assets 13,169 85,557 — 98,726 Liabilities Warrant liabilities — — 906 906 Total liabilities $ — $ — $ 906 $ 906

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease commitments subsequent to March 31, 2021 are as follows (in thousands): 2021 $ 1,146 2022 1,559 2023 1,598 2024 1,638 2025 1,114 Total $ 7,055

Restatement of Previously Iss_2

Restatement of Previously Issued Audited and Unaudited Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2020
Restatement [Abstract]
Summary of restatement of balance sheet	December 31, 2020 balance sheet: As of December 31, 2020 As Previously Restatement As Restated Total assets $ 205,633,422 $ — $ 205,633,422 Liabilities and Shareholders’ Equity Total current liabilities $ 4,896,647 $ — $ 4,896,647 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 47,571,334 47,571,334 Total liabilities 12,090,397 47,571,334 59,661,731 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 188,543,020 (47,571,330 ) 140,971,690 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 127 477 604 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 6,901,127 33,369,400 40,270,527 Accumulated deficit (1,901,752 ) (33,369,881 ) (35,271,633 ) Total shareholders’ equity 5,000,005 (4 ) 5,000,001 Total liabilities and shareholders’ equity $ 205,633,422 $ — $ 205,633,422 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of December 31, 2020 As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 18,854,302 (4,757,133 ) 14,097,169 Ordinary shares—shares issued and outstanding 1,270,698 4,757,133 6,027,831 September 30, 2020 balance sheet: As of September 30, 2020 (Unaudited) As Previously Restatement As Restated Total assets $ 205,813,988 $ — $ 205,813,988 Liabilities and Shareholders’ Equity Total current liabilities $ 3,037,725 $ — $ 3,037,725 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 31,902,349 31,902,349 Total liabilities 10,231,475 31,902,349 42,133,824 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 190,582,510 (31,902,350 ) 158,680,160 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 107 320 427 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 4,861,657 17,700,577 22,562,234 Accumulated deficit 137,736 (17,700,896 ) (17,563,160 ) Total shareholders’ equity 5,000,003 1 5,000,004 Total liabilities and shareholders’ equity $ 205,813,988 $ — $ 205,813,988 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of September 30, 2020 (Unaudited) As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,058,251 (3,190,235 ) 15,868,016 Ordinary shares - shares issued and outstanding 1,066,749 3,190,235 4,256,984 June 30, 2020 balance sheet: As of June 30, 2020 (Unaudited) As Previously Restatement As Restated Total assets $ 206,200,737 $ — $ 206,200,737 Liabilities and Shareholders’ Equity Total current liabilities $ 1,167,702 $ — $ 1,167,702 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 14,380,242 14,380,242 Total liabilities 8,361,452 14,380,242 22,741,694 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 192,839,280 (14,380,240 ) 178,459,040 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 84 145 229 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 2,604,910 178,642 2,783,552 Retained earnings 2,394,508 (178,789 ) 2,215,719 Total shareholders’ equity 5,000,005 (2 ) 5,000,003 Total liabilities and shareholders’ equity $ 206,200,737 $ — $ 206,200,737 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of June 30, 2020 (Unaudited) As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,283,928 (1,438,024 ) 17,845,904 Ordinary shares - shares issued and outstanding 841,072 1,438,024 2,279,096 March 31, 2020 balance sheet: As of March 31, 2020 (Unaudited) As Previously Restatement As Restated Total assets $ 206,287,199 $ — $ 206,287,199 Liabilities and Shareholders’ Equity Total current liabilities $ 1,167,388 $ — $ 1,167,388 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 11,329,888 11,329,888 Total liabilities 8,361,138 11,329,888 19,691,026 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 192,926,060 (11,329,890 ) 181,596,170 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 83 114 197 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 2,518,131 (2,871,677 ) (353,546 ) Retained earnings 2,481,284 2,871,565 5,352,849 Total shareholders’ equity 5,000,001 2 5,000,003 Total liabilities and shareholders’ equity $ 206,287,199 $ — $ 206,287,199 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of March 31, 2020 (Unaudited) As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,292,606 (1,132,989 ) 18,159,617 Ordinary shares - shares issued and outstanding 832,394 1,132,989 1,965,383 December 31, 2019 balance sheet: As of December 31, 2019 As Previously Restatement As Restated Total assets $ 204,765,183 $ — $ 204,765,183 Liabilities and Shareholders’ Equity Total current liabilities $ 979,394 $ — $ 979,394 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 10,349,417 10,349,417 Total liabilities 8,173,144 10,349,417 18,522,561 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 191,592,030 (10,349,410 ) 181,242,620 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 97 104 201 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 3,852,147 (3,852,147 ) — Retained earnings 1,147,262 3,852,036 4,999,298 Total shareholders’ equity 5,000,009 (7 ) 5,000,002 Total liabilities and shareholders’ equity $ 204,765,183 $ — $ 204,765,183 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of December 31, 2019 As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,159,203 (1,034,941 ) 18,124,262 Ordinary shares - shares issued and outstanding 965,797 1,034,941 2,000,738 September 30, 2019 balance sheet: As of September 30, 2019 (Unaudited) As Previously Restatement As Restated Total assets $ 204,094,833 $ — $ 204,094,833 Liabilities and Shareholders’ Equity Total current liabilities $ 1,036,867 $ — $ 1,036,867 Deferred underwriting commissions 7,043,750 — 7,043,750 Deferred legal fees 150,000 — 150,000 Warrant liabilities — 10,840,587 10,840,587 Total liabilities 8,230,617 10,840,587 19,071,204 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 190,864,210 (10,840,590 ) 180,023,620 Shareholders’ equity: Preference shares, $0.0001 par value — — — Class A ordinary shares, $0.0001 par value 104 109 213 Class B ordinary shares, $0.0001 par value 503 — 503 Additional paid-in 4,579,960 (4,411,552 ) 168,408 Retained earnings 419,439 4,411,446 4,830,885 Total shareholders’ equity 5,000,006 3 5,000,009 Total liabilities and shareholders’ equity $ 204,094,833 $ — $ 204,094,833 A reconciliation of the Class A ordinary shares subject to possible redemption outstanding and Class A ordinary shares outstanding is as follows: As of September 30, 2019 (Unaudited) As Previously Restatement As Restated Shares subject to possible redemption - shares outstanding 19,086,421 (1,084,059 ) 18,002,362 Ordinary shares - shares issued and outstanding 1,038,579 1,084,059 2,122,638
Summary of restatement statements of operations	Year ended December 31, 2020 statement of operations: Year Ended December 31, 2020 As Previously Restatement As Restated General and administrative expenses $ 4,791,727 $ — $ 4,791,727 Loss from operations (4,791,727 ) — (4,791,727 ) Change in fair value of warrant liability — (37,221,917 ) (37,221,917 ) Gain on investments (net), dividends and interest, held in Trust Account 1,742,713 — 1,742,713 Net loss $ (3,049,014 ) $ (37,221,917 ) $ (40,270,931 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.07 $ — $ 0.07 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.89 ) $ — $ (8.29 ) Three months ended September 30, 2020 statement of operations: Three Months Ended September 30, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 2,338,004 $ — $ 2,338,004 Loss from operations (2,338,004 ) — (2,338,004 ) Change in fair value of warrant liability — (17,522,107 ) (17,522,107 ) Gain on investments (net), dividends and interest, held in Trust Account 81,232 — 81,232 Net loss $ (2,256,772 ) $ (17,522,107 ) $ (19,778,879 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ — $ — $ — Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.46 ) $ — $ (3.95 ) Nine months ended September 30, 2020 statement of operations: Nine Months Ended September 30, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 2,708,421 $ — $ 2,708,421 Loss from operations (2,708,421 ) — (2,708,421 ) Change in fair value of warrant liability — (21,552,932 ) (21,552,932 ) Gain on investments (net), dividends and interest, held in Trust Account 1,698,895 — 1,698,895 Net loss $ (1,009,526 ) $ (21,552,932 ) $ (22,562,458 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.08 $ — $ 0.08 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.54 ) $ — $ (4.82 ) Three months ended June 30, 2020 statement of operations: Three Months Ended June 30, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 123,634 $ — $ 123,634 Loss from operations (123,634 ) — (123,634 ) Change in fair value of warrant liability — (3,050,354 ) (3,050,354 ) Gain on investments (net), dividends and interest, held in Trust Account 36,858 — 36,858 Net loss $ (86,776 ) $ (3,050,354 ) $ (3,137,130 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.00 $ — $ 0.00 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.02 ) $ — $ (0.63 ) Six months ended June 30, 2020 statement of operations: Six Months Ended June 30, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 370,417 $ — $ 370,417 Loss from operations (370,417 ) — (370,417 ) Change in fair value of warrant liability — (4,030,825 ) (4,030,825 ) Gain on investments (net), dividends and interest, held in Trust Account 1,617,663 — 1,617,663 Net income (loss) $ 1,247,246 $ (4,030,825 ) $ (2,783,579 ) Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.08 $ — $ 0.08 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.07 ) $ — $ (0.87 ) Three months ended March 31, 2020 statement of operations: Three Months Ended March 31, 2020 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 246,783 $ — $ 246,783 Loss from operations (246,783 ) — (246,783 ) Change in fair value of warrant liability — (980,471 ) (980,471 ) Gain on investments (net), dividends and interest, held in Trust Account 1,580,805 — 1,580,805 Net income $ 1,334,022 $ (980,471 ) $ 353,551 Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.08 $ — $ 0.08 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.05 ) $ — $ (0.24 ) Period from April 9, 2019 (inception) to December 31, 2019 statement of operations: Period from April 9, 2019 (inception) to December 31, 2019 As Previously Restatement As Restated General and administrative expenses $ 710,080 $ 600,675 $ 1,310,755 Loss from operations (710,080 ) (600,675 ) (1,310,755 ) Change in fair value of warrant liability — 5,503,291 5,503,291 Gain on investments (net), dividends and interest, held in Trust Account 1,857,342 — 1,857,342 Net income $ 1,147,262 $ 4,902,616 $ 6,049,878 Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.08 $ — $ 0.08 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.08 ) $ — $ 0.90 Three months ended September 30, 2019 statement of operations: Three Months Ended September 30, 2019 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 449,938 $ 600,675 $ 1,050,613 Loss from operations (449,938 ) (600,675 ) (1,050,613 ) Change in fair value of warrant liability — 5,012,121 5,012,121 Gain on investments (net), dividends and interest, held in Trust Account 885,983 — 885,983 Net income $ 436,045 $ 4,411,446 $ 4,847,491 Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.04 $ — $ 0.04 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.09 ) $ — $ 0.79 Period from April 9, 2019 (inception) to September 30, 2019 statement of operations: Period from April 9, 2019 (inception) to September 30, 2019 (Unaudited) As Previously Restatement As Restated General and administrative expenses $ 466,544 $ 600,675 $ 1,067,219 Loss from operations (466,544 ) (600,675 ) (1,067,219 ) Change in fair value of warrant liability — 5,012,121 5,012,121 Gain on investments (net), dividends and interest, held in Trust Account 885,983 — 885,983 Net income $ 419,439 $ 4,411,446 $ 4,830,885 Basic and diluted weighted average shares outstanding of Class A ordinary shares 20,125,000 — 20,125,000 Basic and diluted net income per share, Class A $ 0.04 $ — $ 0.04 Basic and diluted weighted average shares outstanding of Class B ordinary shares 5,031,250 — 5,031,250 Basic and diluted net loss per share, Class B $ (0.09 ) $ — $ 0.79
Summary of restatement of cash flows	Year ended December 31, 2020 statement of cash flows: Year Ended December 31, 2020 As Previously Restatement As Restated Net loss $ (3,049,014 ) $ (37,221,917 ) $ (40,270,931 ) Adjustments to reconcile net loss to net cash used in operating activities (1,742,713 ) 37,221,917 35,479,204 Net cash used in operating activities (777,074 ) — (777,074 ) Net cash provided by investing activities 325,000 — 325,000 Net cash provided by (used in) financing activities — — — Net change in cash $ (452,074 ) $ $ (452,074 ) Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ (3,049,010 ) $ (37,221,920 ) $ (40,270,930 ) Nine months ended September 30, 2020 statement of cash flows: Nine Months Ended September 30, 2020 (Unaudited) As Previously Restatement As Restated Net loss $ (1,009,526 ) $ (21,552,932 ) $ (22,562,458 ) Adjustments to reconcile loss to net cash used in operating activities (1,698,895 ) 21,552,932 19,854,037 Net cash used in operating activities (577,740 ) — (577,740 ) Net cash provided by investing activities 325,000 — 325,000 Net cash provided by (used in) financing activities — — — Net change in cash $ (252,740 ) $ — $ (252,740 ) Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ (1,009,520 ) $ (21,552,940 ) $ (22,562,460 ) Six months ended June 30, 2020 statement of cash flows: Six Months Ended June 30, 2020 (Unaudited) As Previously Restatement As Restated Net income (loss) $ 1,247,246 $ (4,030,825 ) $ (2,783,579 ) Adjustments to reconcile net income (loss) to net cash used in operating activities (1,617,663 ) 4,030,825 2,413,162 Net cash used in operating activities (124,809 ) — (124,809 ) Net cash provided by (used in) investing activities — — — Net cash provided by (used in) financing activities — — — Net change in cash $ (124,809 ) $ — $ (124,809 ) Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ 1,247,250 (4,030,830 ) (2,783,580 ) Three months ended March 31, 2020 statement of cash flows: Three Months Ended March 31, 2020 (Unaudited) As Previously Restatement As Restated Net income $ 1,334,022 $ (980,471 ) $ 353,551 Adjustments to reconcile net income to net cash used in operating activities (1,580,805 ) 980,471 (600,334 ) Net cash used in operating activities (28,639 ) — (28,639 ) Net cash provided by (used in) investing activities — — — Net cash provided by (used in) financing activities — — — Net change in cash $ (28,639 ) $ — $ (28,639 ) Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ 1,334,030 $ (980,480 ) $ 353,550 Period from April 9, 2019 (inception) to December 31, 2019 statement of cash flows: Period from April 9, 2019 (inception) To December 31, 2019 As Previously Restatement As Restated Net income $ 1,147,262 $ 4,902,616 $ 6,049,878 Adjustments to reconcile net income to net cash used in operating activities (1,857,342 ) (4,902,616 ) (6,759,958 ) Net cash used in operating activities (241,682 ) — (241,682 ) Net cash used in investing activities (201,250,000 ) — (201,250,000 ) Net cash provided by financing activities 203,002,023 — 203,002,023 Net change in cash $ 1,510,341 $ — $ 1,510,341 Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ 191,592,030 $ (10,349,410 ) $ 181,242,620 Initial fair value of warrant liability — (15,852,708 ) (15,852,708 ) Period from April 9, 2019 (inception) to September 30, 2019 statement of cash flows: Period from April 9, 2019 (inception) To September 30, 2019 (Unaudited) As Previously Restatement As Restated Net income $ 419,439 $ 4,411,446 $ 4,830,885 Adjustments to reconcile net income to net cash used in operating activities (885,983 ) (4,411,446 ) (5,297,429 ) Net cash used in operating activities (207,200 ) — (207,200 ) Net cash used in investing activities (201,250,000 ) — (201,250,000 ) Net cash provided by financing activities 203,238,700 — 203,238,700 Net change in cash $ 1,781,500 $ — $ 1,781,500 Noncash investing and financing activities: Change in value of Class A ordinary shares subject to possible redemption $ 190,864,210 $ (10,840,590 ) $ 180,023,620 Initial fair value of warrant liability — (15,852,708 ) (15,852,708 )

Basic and Diluted Net Loss pe_2

Basic and Diluted Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three months ended March 31 (in thousands, except share and per share amounts): 2021 2020 Class A Class V Class A Class F Numerator: Net loss attributable to common stockholders $ (49,185 ) $ (2,219 ) $ (4,823 ) $ (1,210 ) Denominator: Weighted average shares outstanding, basic and diluted 146,471,524 6,609,014 27,668,709 6,941,352 Basic and diluted net loss per share $ (0.34 ) $ (0.34 ) $ (0.17 ) $ (0.17 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table discloses securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share: Three Months Ended March 31, 2021 2020 Common stock issued for exercise of stock options subject to nonrecourse promissory notes 3,545,821 16,855,230 Common stock issued for early exercise of stock options 388,839 154,820 Redeemable convertible preferred stock 19,702,603 85,510,700 Stock options 16,361,955 6,969,701 RSUs 3,347,300 — Warrants to purchase Class A common stock 7,733,346 1,895,345 Warrants to purchase redeemable convertible preferred stock — 1,433,585

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2021
Temporary Equity Disclosure [Abstract]
Summary of Redeemable Convertible Preferred Stock	The following table is a summary of Hims’ redeemable convertible preferred stock as of December 31, 2020 (in thousands, except for share data): Series Shares Authorized Shares Issued and Outstanding Aggregate Liquidation Value Proceeds, Net of Issuance Costs Issue Price per Share Series Seed 4,987,477 4,987,477 $ — $ — $ 0.0001 Series A 23,822,492 23,822,492 6,621 5,106 0.2780 Series A-1 5,742,012 5,742,012 753 740 0.1312 Series B 13,270,590 13,270,590 24,600 23,429 1.8538 Series B-1 9,807,952 9,807,952 20,000 14,965 2.0392 Series B-2 13,464,939 13,464,939 51,371 49,911 3.8152 Series C 14,850,340 14,760,594 113,072 92,590 7.6604 Series D 10,051,872 7,472,062 52,035 51,900 6.9639 Total 95,997,674 93,328,118 $ 268,452 $ 238,641

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The grant-date fair value of the Company’s stock options granted was estimated using the following weighted average assumptions for the three months ended March 31, 2021: Expected term (in years) 5.77 Expected volatility 58.87 % Risk-free interest rate 0.83 % Expected dividend yield — %
Share-based Payment Arrangement, Option, Activity	Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Average Exercise Price Weighted Average Contractual Period (in Years) Aggregate Intrinsic Value Outstanding at December 31, 2020 26,459 $ 1.16 8.50 $ 131,770 Recapitalization (14,474 ) 1.41 Outstanding at December 31, 2020 11,985 2.57 8.50 131,770 Granted 423 13.79 Exercised (including early exercised options vested during the period) (384 ) 0.90 Forfeited and expired (56 ) 1.70 Outstanding at March 31, 2021 11,968 3.02 8.37 122,556 Vested and expected to vest as of March 31, 2021 11,968 3.02 8.37 122,556 Exercisable as of March 31, 2021 11,165 $ 2.64 8.37 $ 118,231
Share-based Payment Arrangement, Option, Exercise Price Range	The options outstanding and exercisable as of March 31, 2021 (excluding CEO stock options) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Average Remaining Contractual Life (in Years) Shares Weighted Average Remaining Contractual Life (in Years) $ 0.06 – 0.40 3,236 6.92 3,123 6.92 1.55 – 2.33 3,368 8.07 3,182 8.07 2.43 – 3.65 3,298 9.17 3,295 9.17 8.90 – 13.35 1,888 9.76 1,558 9.75 15.17 – 22.76 178 9.79 7 9.78 11,968 11,165
Schedule of Share-based Payment Award, Equity Instrument Other Than Options, Valuation Assumptions	The following assumptions were used in this valuation: Expected term (in years) 5.00 Expected volatility 60.00 % Risk-free interest rate 0.50 % Expected dividend yield — %
Share-based Payment Arrangement, Restricted Stock Unit, Activity	RSU activity including RSUs outstanding prior to the Merger, earn-out Shares Weighted Average Grant Unvested at December 31, 2020 3,480 $ 5.30 Recapitalization (1,904 ) 5.99 Unvested at December 31, 2020 1,576 11.29 Granted 2,804 14.95 Vested (790 ) 15.66 Unvested at March 31, 2021 3,590 $ 13.16
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the condensed consolidated statements of operations and comprehensive loss for three months ended March 31, 2021 and March 31, 2020 (in thousands): Three Months Ended March 31 2021 2020 Marketing $ 1,846 $ 291 Selling, general, and administrative 32,384 1,113 Total stock-based compensation expense $ 34,230 $ 1,404
Share-based Payment Arrangement, Activity	Vendor warrant activity, excluding any right to receive Merger considerations, is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2020 1,861 0.79 7.01 $ 9,957 Recapitalization (1,018 ) 0.96 Outstanding at December 31, 2020 843 1.75 7.01 $ 9,957 Granted — — Exercised (381 ) 1.75 Forfeited and expired — — Outstanding at March 31, 2021 462 1.75 7.01 $ 5,308 Vested and expected to vest as of March 31, 2021 462 1.75 7.01 $ 5,308 Exercisable as of March 31, 2021 185 1.75 7.01 $ 2,123

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights	As of March 31, 2021, the Company had the following warrants outstanding to purchase shares of Class A common stock (in thousands, except for share and per share amounts): Warrant Type Shares Exercise Price Issued Expiration Vendor 462,335 $ 1.75 September 23, 2019 September 23, 2026 Debt 98,723 6.96 March 12, 2020 November 26, 2026 Public 6,695,915 11.50 July 22, 2019 January 20, 2026 Parent 888,143 11.50 July 22, 2019 January 20, 2026

Description of Organization, _2

Description of Organization, Business Operations and Basis of Presentation - Additional Information (Detail)	Jul. 22, 2019USD ($)$ / sharesshares	Jul. 22, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)DirectorsIndividuals$ / sharesshares	Mar. 31, 2021$ / shares	Jan. 20, 2021$ / sharesshares	Sep. 30, 2020	Apr. 19, 2019$ / shares
Initial public offer, Offering Cost	$ 11,900,000	$ 11,900,000
Securities Maturity Period		185 days
Business Combination Conditions		The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
Temporary Equity Redemption Price Per Share | $ / shares	$ 10	$ 10
Business Combination Covenant terms		In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination.
Description Of Results For Non Compliance With Business Combination		The Company’s Sponsor, officers and directors (the “initial shareholders”) have agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, or July 22, 2021
Working Capital				$ 3,800,000
Interest earned on marketable securities held in Trust Account				3,000,000
Receipts From Capital contributions by Sponsors				25,000
Due To Related Parties Current				62,000
Cash				1,100,000
Working Capital Loan			$ 0	0
Maximum Regulatory Withdrawal				325,000
Regulatory withdrawal, annual limit			325,000	$ 325,000
Recapitalization exchange ratio					0.4530	0.4530
Subscription Agreement With Pipe Investors [Member]
Common stock shares subscribed but no yet issued | shares				7,500,000
Sale of stock issue price per share | $ / shares				$ 10
Common stock value subscribed but no yet issued				$ 75,000,000
Hims Inc [Member]
Business combination cash consideration				$ 75,000,000
Hims Inc [Member] | Equity Incentive Plan [Member]
Business combination employee stock purchase plan as percentage of total equity interests				10.00%
Hims Inc [Member] | Equity Incentive Plan [Member] | Annual Evergreen Provision [Member]
Business combination employee stock purchase plan as percentage of total equity interests				5.00%
Hims Inc [Member] | Employee Stock Purchase Plan [Member]
Business combination employee stock purchase plan as percentage of total equity interests				2.00%
Hims Inc [Member] | Employee Stock Purchase Plan [Member] | Annual Evergreen Provision [Member]
Business combination employee stock purchase plan as percentage of total equity interests				1.00%
Hims Inc [Member] | Before Business Combination [Member]
Number of directors on board needed | Directors				8
Hims Inc [Member] | Additional number Of Directos Post Business Combination [Member]
Number of individuals on board needed | Individuals				4
Proposed Business Acquisition [Member] | New Hims Class A And Class V Common Stock [Member] | Chief Executive Officer Cum Founder [Member]
Common stock shares percentage holding							90.00%
Common Class A [Member]
Common Stock Share, Par value | $ / shares	0.0001	$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Interest earned on marketable securities held in Trust Account			$ 1,900,000	$ 1,700,000
Class of warrants or rights number of shares for each of warrant | shares						0.0028
Common Class A [Member] | Before Business Combination [Member]
Shares subject to possible redemption (shares) | shares				6,193
Shares subject to possible redemption				$ 100,000
Common Class A [Member] | Hims Inc [Member] | New Hims Class A Common Stock [Member]
Business combination total purchase consideration				$ 1,600,000,000
Common Class A [Member] | Hims Inc [Member] | New Hims Class A Common Stock [Member] | Earnout Shares [Member]
Business combination contingent consideration shares issued or issuable | shares				16,000,000
Number Of Consecutive Share Trading Days				10 days
Number of trading days				20 days
Common Class A [Member] | Hims Inc [Member] | New Hims Class A Common Stock [Member] | Earnout Shares [Member] | Contingent Earnout Vesting Percentage One [Member]
Share trading price | $ / shares				$ 15
Common Class A [Member] | Hims Inc [Member] | New Hims Class A Common Stock [Member] | Earnout Shares [Member] | Contingent Earnout Vesting Percentage Two [Member]
Share trading price | $ / shares				17.50
Common Class A [Member] | Hims Inc [Member] | New Hims Class A Common Stock [Member] | Earnout Shares [Member] | Contingent Earnout Vesting Percentage Three [Member]
Share trading price | $ / shares				$ 20
Common Class A [Member] | Proposed Business Acquisition [Member] | Hims Inc [Member]
Class of warrants or rights number of shares for each of warrant | shares				1
Common Class A [Member] | Proposed Business Acquisition [Member] | Hims Inc [Member] | New Hims Class A Common Stock [Member]
Common stock per share in the resulting company				1
Common Class B [Member]
Common Stock Share, Par value | $ / shares				$ 0.0001				$ 0.0001
Common Class B [Member] | Hims Inc [Member] | New Hims Class A Common Stock [Member] | Sponsor [Member]
Percentage of shares subject to forfeiture				25.00%
Maximum [Member]
Percentage of Temporary Equity Redemption		15.00%
Dissolution Expense		$ 100,000
Private Placement [Member]
Warrants Issued | shares		4,016,667
Warrants Price | $ / shares		$ 1.50
Proceeds From Issuance Of Private Placement Warrants		$ 6,030,000
Sale of stock issue price per share | $ / shares						$ 10
IPO [Member]
Proceeds From Issuance Initial Public Offering		$ 201,250,000
Initial public offer,Share Price | $ / shares	$ 10	$ 10
Proceeds From Issuance Of Private Placement Warrants		$ 201,250,000
Initial public offer, shares Issued | shares	20,125,000
Over-Allotment Option [Member]
Deferred Underwriting Commission		$ 7,040,000
Initial public offer, shares Issued | shares	2,625,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2020
Revenue from Contract with Customer, Excluding Assessed Tax	$ 52,314	$ 30,063
Online
Revenue from Contract with Customer, Excluding Assessed Tax	50,680	28,524
Wholesale
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,634	$ 1,539

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		4 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2020
Federal Deposit Insurance Coverage Amount			$ 250,000	$ 250,000	$ 250,000
Interest earned on marketable securities held in Trust Account					$ 3,000,000
Temporary shares outstanding	0				93,328,118
Regulatory withdrawal, annual limit				325,000	$ 325,000
Net (loss) income	$ 51,404,000	$ 6,033,000
Restricted investments term					185 days
Gain loss on investments net dividend and interest held in trust account	(2,905,000)	230,000
Inventory write-down	100,000	100,000
Other than temporary impairment losses, investments	$ 0	0
Stock options
Award vesting period (in years)	4 years
Common Class A [Member]
Interest earned on marketable securities held in Trust Account				$ 1,900,000	$ 1,700,000
Temporary shares outstanding			18,124,262	18,124,262	14,097,169
Net (loss) income	$ 49,185,000	$ 4,823,000
Interest earned on marketable securities held in Trust Account Net of regulatory withdrawal			$ 1,500,000		$ 1,400,000
Gain loss on investments net dividend and interest held in trust account				$ 1,500,000	1,400,000
Common Class B [Member]
Net (loss) income				6,000,000	40,300,000
Net Income attributable to ordinary holders				4,500,000	41,700,000
Cash and Cash Equivalents [Member]
Cash held in trust			$ 17,000	$ 17,000	$ 24
Common Stock [Member]
Antidilutive securities				10,725,000	10,725,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Jan. 20, 2021	Sep. 23, 2019	Jul. 22, 2019	Jul. 17, 2019	Apr. 19, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Jun. 26, 2019
Related party Transaction Expense				$ 10,000	$ 25,000
Percentage Of Founder Shares On Outstanding Shares													20.00%
Advances From Related Party Agreed Amount									$ 300,000
Due To Related Parties Current									$ 62,000
Common Stock Shares Resale or Transfer Share Price Threshold									$ 12
Related Party Expense In Transaction				10,000	25,000
Related party transaction, expenses from transactions with related party				$ 10,000	$ 25,000
Repayment of promissory notes associated with vested and unvested shares						$ 1,193,000	$ 0
Conversion of convertible securities						249,837,000	4,500,000
Maximum [Member]
Founder Shares Subject To Redemption													656,250
Affiliated Entity [Member]
Related party Transaction Expense						800,000	800,000
Related Party Expense In Transaction						800,000	800,000
Related party transaction, expenses from transactions with related party						$ 800,000	800,000
Affiliated Entity [Member] | Redeemable Common Stock Transaction [Member]
Sale of stock, put right period						6 months
Affiliated Entity [Member] | Operational Support [Member]
Accounts payable, related parties						$ 0			$ 0
Affiliated Entity [Member] | Identity Verification Services [Member]
Related party transaction, purchases from related party						100,000	100,000
Accounts payable, related parties						$ 100,000			$ 100,000
Management [Member] | Nonrecourse RelatedParty Promissory Notes [Member]
Options outstanding (in shares)									16,345,627
Share-based compensation arrangement by share-based payment award, options, outstanding, value									$ 7,200,000
Repayment of promissory notes associated with vested and unvested shares	$ 1,200,000
Forfeiture of related-party promissory notes (in shares)	370,734
Management [Member] | Nonrecourse RelatedParty Promissory Notes [Member] | Maximum [Member]
Related party transaction, rate									3.02%
Management [Member] | Nonrecourse RelatedParty Promissory Notes [Member] | Minimum [Member]
Related party transaction, rate									2.21%
CEO And Director | Redeemable Common Stock Transaction [Member]
Related party Transaction Expense		$ 3,000,000
Related Party Expense In Transaction		3,000,000
Related party transaction, expenses from transactions with related party		$ 3,000,000
Expense Reimbursement Agreement [Member]
Due To Related Parties Current									$ 62,000
Administrative Support Agreement [Member]
Related party Transaction Expense								$ 55,000	120,000
Accrued expenses—related party								55,000	60,000
Payment of outstanding accrued administrative support fees									115,000
Related Party Expense In Transaction								55,000	120,000
Related party transaction, expenses from transactions with related party								$ 55,000	120,000
Private Placement [Member]
Warrants Issued			4,016,667
Warrants Price			$ 1.50
Proceeds From Issuance Of Private Placement Warrants			$ 6,030,000
Working Capital Loans Eligible For Conversion Into Warrants									$ 1,500,000
Warrant Conversion Price			$ 1.50
Sale of stock, number of shares issued in transaction (in shares)	7,500,000
Sale of stock, price per share (in dollars per share)	$ 10
Sale of stock, consideration received on transaction	$ 75,000,000
Sale of Stock from CEO and Member Of Board of Directors [Member] | Chief Executive Officer And Director
Sale of stock, number of shares issued in transaction (in shares)		737,058
Sale of stock, price per share (in dollars per share)		$ 6.11
Sale of stock, consideration received on transaction		$ 4,500,000
Common Class A [Member]
Common stock, shares outstanding						182,973,780			46,025,754
Common stock par value	$ 0.0001		0.0001			$ 0.0001			$ 0.0001
Class of warrants redemption exercise price			$ 11.50
Common Class B [Member]
Common stock, shares outstanding					4,312,500			5,031,250	5,031,250
Common stock par value					$ 0.0001				$ 0.0001
Redeemable Class A Common Stock [Member]
Conversion of convertible securities							$ (4,500,000)
Previously Reported [Member]
Common stock, shares outstanding							832,394	965,797	1,270,698	1,066,749	841,072	1,038,579
Previously Reported [Member] | Common Class B [Member]
Common stock, shares outstanding													4,312,500
Restatement Adjustment [Member] | Common Class B [Member]
Common stock, shares outstanding													5,031,250

Recapitalization - Additional I

Recapitalization - Additional Information (Details) $ / shares in Units, $ in Thousands	Jan. 20, 2021USD ($)d$ / sharesshares	Mar. 31, 2021USD ($)d$ / shares	Mar. 31, 2020USD ($)	Jan. 19, 2021$ / shares	Dec. 31, 2020$ / shares	Jul. 22, 2019$ / shares
Reverse ecapitalization Percentage Of Voting Interests Acquired	1
Reverse Recapitalization Transaction Costs | $	$ 16,200
Recapitalization exchange ratio	0.4530	0.4530
Proceeds From Issuance Of Common Stock Recapitalization | $	$ 197,700	$ 197,686	$ 0
Reverse recapitalization, contingent consideration, equity (in shares) | shares	16,000,000
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share)	$ 15	$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share)	17.50	17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share)	$ 20	$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days | d	10	10
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading day period | d	20
Private Placement [Member]
Sale of stock, number of shares issued in transaction (in shares) | shares	7,500,000
Sale of stock, price per share (in dollars per share)	$ 10
Sale of stock, consideration received on transaction | $	$ 75,000
Chief Executive Officer [Member]
Recapitalization exchange ratio	0.4530
Common Class A [Member]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001			$ 0.0001	$ 0.0001
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares	0.0028
Common Class A [Member] | Hims Stockholders [Member] | Parent Warrants [Member]
Shares (in shares) | shares	888,143
Common Class A [Member] | Hims Warrant Holders [Member] | Parent Warrants [Member]
Shares (in shares) | shares	3,443
Common Class A [Member] | Hims Option And R S U Holders [Member] | Parent Warrants Restricted Stock Units [Member]
Shares (in shares) | shares	35,000
Common Class A [Member] | Hims Inc [Member]
Common stock, par value (in dollars per share)				$ 0.000001
Common Class A [Member] | Chief Executive Officer [Member]
Common stock, par value (in dollars per share)	$ 0.0001
Common Class V [Member]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common Class V [Member] | Hims Inc [Member]
Common stock, par value (in dollars per share)				$ 0.000001
Common Class A And V [Member] | Common Stock [Member]
Recapitalization, contingent consideration, equity, exchange ratio	0.0443

Investments - Short-term Invest

Investments - Short-term Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Marketable Securities [Line Items]
Adjusted Cost	$ 235,156	$ 72,859
Unrealized Gains	3	7
Unrealized Losses	(62)	(2)
Fair Value	235,097	72,864
Corporate bonds
Marketable Securities [Line Items]
Adjusted Cost	177,273	55,224
Unrealized Gains	1	5
Unrealized Losses	(53)	(2)
Fair Value	177,221	55,227
Government bonds
Marketable Securities [Line Items]
Adjusted Cost	40,955	14,121
Unrealized Gains	2	2
Unrealized Losses	(5)	0
Fair Value	40,952	14,123
Asset-backed bonds
Marketable Securities [Line Items]
Adjusted Cost	16,928	3,514
Unrealized Gains	0	0
Unrealized Losses	(4)	0
Fair Value	$ 16,924	$ 3,514

Inventory - Schedule of Invento

Inventory - Schedule of Inventory, Current (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Finished goods	$ 3,546	$ 2,856
Raw materials	977	687
Total inventory	$ 4,523	$ 3,543

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Trade and other receivables, net	$ 942	$ 1,147
Prepaid expenses	8,650	2,691
Vendor deposits	2,810	1,395
Other current assets	5	171
Total prepaid expenses and other current assets	$ 12,407	$ 5,404

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Marketing expenses	$ 1,514	$ 1,122
Professional services	1,480	1,241
Payroll costs	1,250	919
Tax payables	729	651
Warrant exercise deposit liability	0	664
Other accrued liabilities	850	387
Total accrued liabilities	$ 5,823	$ 4,984

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Variable Interest Entity [Line Items]
Current assets	$ 340,196		$ 113,084
Assets	345,900		118,697
Current liabilities	19,680		15,228
Liabilities	53,434		15,609
Net Loss	(51,404)	$ (6,033)
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Current assets	500		500
Assets	1,400		1,400
Current liabilities	1,100		800
Liabilities	1,500		$ 1,200
Net Loss	1,800	2,500
Consolidation, Eliminations [Member] | Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Payments to suppliers	$ 3,400	$ 300
Affiliated Medical Groups [Member]
Variable Interest Entity [Line Items]
Percentage owned by licensed physicians	100.00%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of fair value assets measured on recurring basis (Detail) - Fair Value, Recurring [Member] - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 321,965,000	$ 98,726,000
Liabilities, Fair Value Disclosure [Abstract]
Total liabilities	33,370,000	906,000
Warrant Liabilities [Member]
Liabilities, Fair Value Disclosure [Abstract]
Total liabilities	33,370,000	906,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account		204,525,055	$ 203,107,342
Total assets	75,786,000	13,169,000
Liabilities, Fair Value Disclosure [Abstract]
Warrant Liability		26,162,499	6,372,917
Total liabilities	33,370,000
Fair Value, Inputs, Level 1 [Member] | Public Warrants [Member]
Liabilities, Fair Value Disclosure [Abstract]
Warrant Liability		26,162,499	6,372,917
Fair Value, Inputs, Level 1 [Member] | Warrant Liabilities [Member]
Liabilities, Fair Value Disclosure [Abstract]
Total liabilities	33,370,000	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	246,179,000	85,557,000
Liabilities, Fair Value Disclosure [Abstract]
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member] | Warrant Liabilities [Member]
Liabilities, Fair Value Disclosure [Abstract]
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Warrant Liability		21,408,835	3,976,500
Total liabilities	0	906,000
Fair Value, Inputs, Level 3 [Member] | Private Placement Warrants [Member]
Liabilities, Fair Value Disclosure [Abstract]
Warrant Liability		21,408,835	3,976,500
Fair Value, Inputs, Level 3 [Member] | Warrant Liabilities [Member]
Liabilities, Fair Value Disclosure [Abstract]
Total liabilities	0	906,000
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account		204,525,031	203,090,272
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents	74,930,000	12,163,000
Restricted Cash	856,000	1,006,000
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents	74,930,000	12,163,000
Restricted Cash	856,000	1,006,000
Assets held in Trust Account		24	$ 17,070
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents	0	0
Restricted Cash	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents	0	0
Restricted Cash	0	0
Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments	177,221,000	55,227,000
Corporate bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments	0	0
Corporate bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments	177,221,000	55,227,000
Corporate bonds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments	0	0
Government bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents	11,082,000	12,693,000
Short-term Investments	40,952,000	14,123,000
Government bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents	0	0
Short-term Investments	0	0
Government bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents	11,082,000	12,693,000
Short-term Investments	40,952,000	14,123,000
Government bonds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents	0	0
Short-term Investments	0	0
Asset-backed bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments	16,924,000	3,514,000
Asset-backed bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments	0	0
Asset-backed bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments	16,924,000	3,514,000
Asset-backed bonds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term Investments	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of quantitative information regarding Level 3 fair value measurement inputs of Warrants (Detail)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2019	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term	1 month 27 days
Volatility	65.00%
Risk-free rate	0.03%
Dividend yield	0.00%
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term		1 year 9 months	3 months 21 days
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Volatility		29.60%	55.00%
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free rate		0.14%	0.10%
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Dividend yield		0.00%	0.00%

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in fair value of warrants | $	$ 0.3
Public Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share) | $ / shares	$ 4.40

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of fair value of the warrant liabilities (Detail) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2019	Dec. 31, 2020
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31,2020	$ 906,000
Conversion of Series D preferred stock warrants to Class A common stock warrants	(1,160,000)
Private Placement Warrants and Public Warrants	51,814,000
Exercised warrants	(20,871,000)
Increase in fair value of warrants	2,681,000
Balance at March 31, 2021	33,370,000		$ 906,000
Warrant [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 47,571,334		10,349,417
Issuance of Public and Private Placement Warrants		$ 15,852,708
Change in fair value		(5,503,291)	37,221,917
Ending balance		$ 10,349,417	$ 47,571,334

Borrowing Arrangements (Details

Borrowing Arrangements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 12, 2021	Jan. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 12, 2020	Feb. 29, 2020	Nov. 30, 2019	Nov. 27, 2019
Line of Credit Facility [Line Items]
Restricted cash, noncurrent	$ 856			$ 1,006
Series C Preferred Stock Warrants [Member]
Line of Credit Facility [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares)						89,747	1,341,865	89,747	89,747
Class of warrant or right, exercise price of warrants or rights (in dollars per share)						$ 7.67			$ 7.67
Series D Preferred Stock Warrants [Member]
Line of Credit Facility [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares)						98,723
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 6.96				$ 6.96
Business Credit Card [Member] | Line of Credit [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	3,500		$ 5,000						$ 2,000
Debt instrument, covenant, required collateral amount	200		$ 200
Capital Agreement, 2019 | Notes Payable, Other Payables [Member]
Line of Credit Facility [Line Items]
Debt instrument, maximum borrowing capacity									50,000
Debt, long-term and short-term, combined amount				$ 0
Capital Agreement, 2019, Tranche One | Notes Payable, Other Payables [Member]
Line of Credit Facility [Line Items]
Debt instrument, maximum borrowing capacity									25,000
Capital Agreement, 2019, Tranche Two | Notes Payable, Other Payables [Member]
Line of Credit Facility [Line Items]
Debt instrument, maximum borrowing capacity									25,000
Letter of Credit [Member] | Line of Credit [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity					$ 3,500				$ 2,000
Proceeds from issuance of debt	800
Debt instrument, covenant, required collateral amount	800
Restricted cash, noncurrent	$ 800

Commitments and Contingencies (

Commitments and Contingencies (Details)	1 Months Ended		3 Months Ended
	Jan. 31, 2020	Jul. 22, 2019USD ($)$ / sharesshares	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Jan. 31, 2021USD ($)ft²	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Deferred Legal Fees						$ 150,000	$ 150,000
Operating leases, rent expense			$ 400,000	$ 700,000
Operating lease, term of contract	63 months
Operating leases, future minimum payments due			7,055,000		$ 7,900,000
Lessee, operating lease, period for payments net of rent abatement	3 months
Rent expense, annual escalation, percent	2.50%
Operating lease, renewal term	5 years
Purchase obligation			$ 1,000,000
New Albany Ohio [Member]
Area of real estate property | ft²					302,880
Over-Allotment Option [Member]
Capital Units Issued | shares		2,625,000
Underwriting discount per unit | $ / shares		$ 0.20
Underwriting income loss		$ 4,025,000
Deferred Underwriting Commission		$ 7,040,000
Over-Allotment Option [Member] | Additional [Member]
Underwriting discount per unit | $ / shares		$ 0.35
Deferred Underwriting Commission		$ 7,040,000

Commitment and Contingencies -

Commitment and Contingencies - Future Minimum Lease Commitments (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Jan. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
2021	$ 1,146
2022	1,559
2023	1,598
2024	1,638
2025	1,114
Total	$ 7,055	$ 7,900

Stock-Based Compensation - 2017

Stock-Based Compensation - 2017 Stock Plan and 2020 Equity Incentive Plan (Details) - shares	1 Months Ended	3 Months Ended
	Jan. 31, 2021	Mar. 31, 2021
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)		10 years
2020 Equity Incentive Plan and 2017 Stock Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)		5 years
2020 Equity Incentive Plan and 2017 Stock Plan | Minimum | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock, percent		110.00%
Stockholders equity ownership, percent		10.00%
2020 Equity Incentive Plan and 2017 Stock Plan | Minimum | Stock Options and Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock, percent		100.00%
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	21,000,000	21,055,645
Percentage increase in authorized shares of common stock	5.00%
Number of shares available for grant (in shares)		18,581,886
Stock Plan, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)	19,000,000
Number of authorized shares transferred between plans (in shares)	55,645
Number of shares available for grant (in shares)		0

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options Narrative (Details)	Jun. 17, 2020USD ($)$ / sharesshares	Feb. 28, 2021shares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2020USD ($)	Jan. 20, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense			$ 34,230,000	$ 1,404,000
Recapitalization exchange ratio			0.4530		0.4530
Weighted average grant date fair value (in dollars per share) | $ / shares			$ 7.34
Intrinsic value of exercises during period			$ 2,000,000
Share-based payment arrangement, exercise of option, tax benefit			$ 0
Early exercises of nonvested options (in shares) | shares			301,893
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recapitalization exchange ratio					0.4530
Exercise of vested stock options (in shares) | shares		3,246,139
Grant date fair value	$ 16,600,000
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 4,200,000
Options outstanding (in shares) | shares			1,623,070
Chief Executive Officer | June 17 2020 Grant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) | shares	3,246,139
Awards granted (in dollars per share) | $ / shares	$ 2.43
Acquisition with shares consideration threshold (in dollars per share) | $ / shares	$ 22.99
Chief Executive Officer | June 17 2020 Grant Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) | shares	1,623,070
Awards granted (in dollars per share) | $ / shares	$ 2.43
Acquisition with shares consideration threshold (in dollars per share) | $ / shares	$ 38.31
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 20,500,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)			10 years
Award vesting period (in years)			4 years
Stock options | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			3 years 14 days
Stock options | Chief Executive Officer | June 17 2020 Grant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense			$ 11,300,000
Stock options | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			3 years 3 months 29 days
Stock options | New Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Award vesting rights, monthly percentage			2.083%
Stock options | New Employee | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			1 year
Award vesting rights, monthly percentage			25.00%
Stock options | Current Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, monthly percentage			2.083%

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted Average Fair Value Assumptions (Details)	3 Months Ended
	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	1 month 27 days
Risk-free interest rate	0.03%
Expected dividend yield	0.00%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 9 months 7 days
Expected volatility	58.87%
Risk-free interest rate	0.83%
Expected dividend yield	0.00%

Stock-Based Compensation - Opti

Stock-Based Compensation - Option Activity (Details) - Employee, excluding CEO - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Shares
Beginning balance (in shares)	11,985
Granted (in shares)	423
Exercised (in shares)	(384)
Forfeited and expired (in shares)	(56)
Ending balance (in shares)	11,968	11,985
Vested and expected to vest at the end of the period (in shares)	11,968
Exercisable at the end of the period (in shares)	11,165
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 2.57
Granted (in dollars per share)	13.79
Exercised (in dollars per share)	0.90
Forfeited and expired (in dollars per share)	1.70
Ending balance (in dollars per share)	3.02	$ 2.57
Vested and expected to vest at the end of the period (in dollars per share)	3.02
Exercisable at the end of the period (in dollars per share)	$ 2.64
Weighted Average Contractual Period (in Years)
Outstanding balance (in years)	8 years 4 months 13 days	8 years 6 months
Vested and expected to vested at the end of the period (in years)	8 years 4 months 13 days
Exercisable at the end of the period (in years)	8 years 4 months 13 days
Aggregate Intrinsic Value
Outstanding balance	$ 122,556	$ 131,770
Vested and expected to vest at the end of the period	122,556
Exercisable at the end of the period	$ 118,231
Previously Reported
Shares
Beginning balance (in shares)	26,459
Ending balance (in shares)		26,459
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 1.16
Ending balance (in dollars per share)		$ 1.16
Weighted Average Contractual Period (in Years)
Outstanding balance (in years)		8 years 6 months
Aggregate Intrinsic Value
Outstanding balance		$ 131,770
Revision of Prior Period, Adjustment
Shares
Beginning balance (in shares)	(14,474)
Ending balance (in shares)		(14,474)
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 1.41
Ending balance (in dollars per share)		$ 1.41

Stock-Based Compensation - Exer

Stock-Based Compensation - Exercise Price Range of Options Outstanding and Exercisable (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Options Outstanding
Shares (in shares)	11,968
Options Exercisable
Shares (in shares)	11,165
Exercise Price Range $0.06 to $0.40
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 0.06
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 0.40
Options Outstanding
Shares (in shares)	3,236
Weighted Average Remaining Contractual Life (in years)	6 years 11 months 1 day
Options Exercisable
Shares (in shares)	3,123
Weighted Average Remaining Contractual Life (in years)	6 years 11 months 1 day
Exercise Price Range $1.55 to $2.33
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 1.55
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 2.33
Options Outstanding
Shares (in shares)	3,368
Weighted Average Remaining Contractual Life (in years)	8 years 25 days
Options Exercisable
Shares (in shares)	3,182
Weighted Average Remaining Contractual Life (in years)	8 years 25 days
Exercise Price Range $2.43 to $3.65
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 2.43
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 3.65
Options Outstanding
Shares (in shares)	3,298
Weighted Average Remaining Contractual Life (in years)	9 years 2 months 1 day
Options Exercisable
Shares (in shares)	3,295
Weighted Average Remaining Contractual Life (in years)	9 years 2 months 1 day
Exercise Price Range $8.90 to $13.35
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 8.90
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 13.35
Options Outstanding
Shares (in shares)	1,888
Weighted Average Remaining Contractual Life (in years)	9 years 9 months 3 days
Options Exercisable
Shares (in shares)	1,558
Weighted Average Remaining Contractual Life (in years)	9 years 9 months
Exercise Price Range $15.17 to $22.76
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 15.17
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 22.76
Options Outstanding
Shares (in shares)	178
Weighted Average Remaining Contractual Life (in years)	9 years 9 months 14 days
Options Exercisable
Shares (in shares)	7
Weighted Average Remaining Contractual Life (in years)	9 years 9 months 10 days

Stock-Based Compensation - RSUs

Stock-Based Compensation - RSUs Narrative (Details) $ / shares in Units, $ in Millions	Jan. 20, 2021d$ / shares	Jan. 31, 2021shares	Mar. 31, 2021USD ($)d$ / sharesshares	Dec. 31, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recapitalization exchange ratio	0.4530		0.4530
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share) | $ / shares	$ 15		$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share) | $ / shares	17.50		17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share) | $ / shares	$ 20		$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days | d	10		10
Reverse recapitalization, contingent consideration, equity, earnout period, threshold consecutive trading days | d	20		20
Reverse recapitalization, contingent consideration, equity, earnout period	5 years		5 years
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recapitalization exchange ratio	0.4530
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Share price (in dollars per share) | $ / shares			$ 16.38
Vested (in shares)			790,000
Granted (in shares)			2,804,000	45,297
Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount | $			$ 40.1
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			3 years 7 months 9 days
RSUs | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			1 year
Awards vesting rights, percentage			25.00%
Earn Out Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)			317,539
Earn Out Restricted Stock Units | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)			476,308
Earn Out Restricted Stock Units | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		4,431
Parent Warrant Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)			6,319
Parent Warrant Restricted Stock Units | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)			9,478
Parent Warrant Restricted Stock Units | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		88

Stock-Based Compensation - RS_2

Stock-Based Compensation - RSUs Weighted Average Fair Value Assumptions (Details)	3 Months Ended
	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	1 month 27 days
Risk-free interest rate	0.03%
Expected dividend yield	0.00%
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years
Expected volatility	60.00%
Risk-free interest rate	0.50%
Expected dividend yield	0.00%

Stock-Based Compensation - RS_3

Stock-Based Compensation - RSUs Activity (Details) - RSUs - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Shares
Beginning balance (in shares)	1,576,000
Granted (in shares)	2,804,000	45,297
Vested (in shares)	(790,000)
Ending balance (in shares)	3,590,000	1,576,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance (in dollars per share)	$ 11.29
Granted (in dollars per share)	14.95
Vested (in dollars per share)	15.66
Ending balance (in dollars per share)	$ 13.16	$ 11.29
Previously Reported
Shares
Beginning balance (in shares)	3,480,000
Ending balance (in shares)		3,480,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance (in dollars per share)	$ 5.30
Ending balance (in dollars per share)		$ 5.30
Revision of Prior Period, Adjustment
Shares
Beginning balance (in shares)	(1,904,000)
Ending balance (in shares)		(1,904,000)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance (in dollars per share)	$ 5.99
Ending balance (in dollars per share)		$ 5.99

Stock-Based Compensation - Vend

Stock-Based Compensation - Vendor Warrants Narrative (Details) $ / shares in Units, $ in Millions	Jan. 20, 2021d$ / shares	Mar. 31, 2021USD ($)d$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recapitalization exchange ratio	0.4530	0.4530
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share)	$ 15	$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share)	17.50	17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share)	$ 20	$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days | d	10	10
Reverse recapitalization, contingent consideration, equity, earnout period, threshold consecutive trading days | d	20	20
Reverse recapitalization, contingent consideration, equity, earnout period	5 years	5 years
Earn-Out And Parent Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares) | shares		48,062
Vendor Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount | $		$ 0.5
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition		5 months 23 days

Stock-Based Compensation - Ve_2

Stock-Based Compensation - Vendor Warrant Activity (Details) - Vendor Warrants - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Shares
Beginning balance (in shares)	843
Granted (in shares)	0
Exercised (in shares)	(381)
Forfeited and expired (in shares)	0
Ending balance (in shares)	462	843
Vested and expected to vest at the end of period (in shares)	462
Exercisable at the end of period (in shares)	185
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 1.75
Granted (in dollars per share)	0
Exercised (in dollars per share)	1.75
Forfeited and expired (in dollars per share)	0
Ending balance (in dollars per share)		$ 1.75
Vested and expected to vest at the end of period (in dollars per share)	1.75
Exercisable at the end of period (in dollars per share)	$ 1.75
Weighted Average Contractual Term (in Years)
Outstanding (in years)	7 years 3 days	7 years 3 days
Vested and expected to vest at the end of period (in years)	7 years 3 days
Exercisable at the end of period (in years)	7 years 3 days
Aggregate Intrinsic Value
Outstanding	$ 5,308	$ 9,957
Vested and expected to vest and the end of period	5,308
Exercisable at the end of period	$ 2,123
Previously Reported
Shares
Beginning balance (in shares)		1,861
Weighted Average Exercise Price
Beginning balance (in dollars per share)		$ 0.79
Weighted Average Contractual Term (in Years)
Outstanding (in years)		7 years 3 days
Aggregate Intrinsic Value
Outstanding		$ 9,957
Revision of Prior Period, Adjustment
Shares
Beginning balance (in shares)		(1,018)
Weighted Average Exercise Price
Beginning balance (in dollars per share)		$ 0.96

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Employees and Nonemployees (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 34,230	$ 1,404
Marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	1,846	291
Selling, general, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 32,384	$ 1,113

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Mar. 31, 2021
Temporary Equity [Line Items]
Shares Authorized	95,997,674	275,000,000
Temporary shares outstanding	93,328,118	0
Aggregate Liquidation Value	$ 268,452	$ 0
Proceeds, Net of Issuance Costs	$ 238,641
Series Seed Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	4,987,477
Temporary shares outstanding	4,987,477
Aggregate Liquidation Value	$ 0
Proceeds, Net of Issuance Costs	$ 0
Issue Price per Share (in dollars per share)	0.0001
Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	23,822,492
Temporary shares outstanding	23,822,492
Aggregate Liquidation Value	$ 6,621
Proceeds, Net of Issuance Costs	$ 5,106
Issue Price per Share (in dollars per share)	0.2780
SeriesA1PreferredStock [Member]
Temporary Equity [Line Items]
Shares Authorized	5,742,012
Temporary shares outstanding	5,742,012
Aggregate Liquidation Value	$ 753
Proceeds, Net of Issuance Costs	$ 740
Issue Price per Share (in dollars per share)	0.1312
Series B Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	13,270,590
Temporary shares outstanding	13,270,590
Aggregate Liquidation Value	$ 24,600
Proceeds, Net of Issuance Costs	$ 23,429
Issue Price per Share (in dollars per share)	1.8538
SeriesB1PreferredStock [Member]
Temporary Equity [Line Items]
Shares Authorized	9,807,952
Temporary shares outstanding	9,807,952
Aggregate Liquidation Value	$ 20,000
Proceeds, Net of Issuance Costs	$ 14,965
Issue Price per Share (in dollars per share)	2.0392
SeriesB2PreferredStock [Member]
Temporary Equity [Line Items]
Shares Authorized	13,464,939
Temporary shares outstanding	13,464,939
Aggregate Liquidation Value	$ 51,371
Proceeds, Net of Issuance Costs	$ 49,911
Issue Price per Share (in dollars per share)	3.8152
Series C Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	14,850,340
Temporary shares outstanding	14,760,594
Aggregate Liquidation Value	$ 113,072
Proceeds, Net of Issuance Costs	$ 92,590
Issue Price per Share (in dollars per share)	7.6604
Series D Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	10,051,872
Temporary shares outstanding	7,472,062
Aggregate Liquidation Value	$ 52,035
Proceeds, Net of Issuance Costs	$ 51,900
Issue Price per Share (in dollars per share)	6.9639

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock - Additional Information (Details) $ / shares in Units, $ in Millions	1 Months Ended	5 Months Ended	12 Months Ended
	Feb. 29, 2020USD ($)shares	Jul. 31, 2020USD ($)shares	Dec. 31, 2020USD ($)shares	Mar. 31, 2021shares	Mar. 12, 2021$ / shares	Jan. 20, 2021	Mar. 12, 2020$ / sharesshares	Mar. 01, 2020USD ($)	Nov. 30, 2019shares	Nov. 27, 2019$ / sharesshares
Temporary Equity [Line Items]
Shares Authorized			95,997,674	275,000,000
Shares Issued (in shares)			93,328,118	0
Shares Outstanding (in Shares)			93,328,118	0
Recapitalization Exchange Conversion Basis						1
Recapitalization Exchange Ratio				0.4530		0.4530
Series C Preferred Stock Warrants [Member]
Temporary Equity [Line Items]
Warrants and Rights Outstanding | $	$ 10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	1,341,865						89,747		89,747	89,747
Class of warrants redemption exercise price | $ / shares							$ 7.67			$ 7.67
Series D Preferred Stock Warrants [Member]
Temporary Equity [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)							98,723
Class of warrants redemption exercise price | $ / shares					$ 6.96		$ 6.96
Series D Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized			10,051,872
Shares Issued (in shares)		7,472,062	7,472,062
Shares Outstanding (in Shares)			7,472,062
Proceeds From Issuance Of Temporary Equity | $		$ 51.9	$ 51.9
Series C Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized			14,850,340
Shares Outstanding (in Shares)			14,760,594
Warrants and Rights Outstanding | $								$ 11.3
Conversion of convertible securities	1,341,865
Proceeds From Conversion Of Convertible Securities | $	$ 0.1

Common Stock - Additional Infor

Common Stock - Additional Information (Details) $ / shares in Units, $ in Thousands	Jan. 20, 2021USD ($)$ / sharesshares	May 31, 2020USD ($)shares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Dec. 31, 2020USD ($)$ / sharesshares	Jan. 19, 2021Common_Stock_Class	Sep. 30, 2020shares	Jun. 30, 2020shares	Dec. 31, 2019shares	Sep. 30, 2019shares	Jul. 22, 2019$ / shares	Jun. 26, 2019shares	Apr. 19, 2019$ / sharesshares
Common stock conversion description					20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Initial Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity- linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor upon conversion of Working Capital Loans.
Preferred shares authorized					1,000,000
Preference shares issued									0
Preference shares outstanding									0
Temporary Equity Outstanding			0		93,328,118
Number of classes of common stock | Common_Stock_Class						2
Payments for repurchase of common stock | $			$ 22,027	$ 0
Previously Reported [Member]
Common Shares Outstanding				832,394	1,270,698		1,066,749	841,072	965,797	1,038,579
Private Placement Warrants [Member]
Class of warrants redemption exercise price | $ / shares					$ 0.01
Class of warrant exercise price threshold | $ / shares					10
Public Warrants [Member]
Class of warrants redemption exercise price | $ / shares					0.10
Class of warrant exercise price threshold | $ / shares					$ 18
Former Executive Officer [Member] | Repurchase Of Stock [Member]
Notes receivable, amount of principal payment canceled | $		$ 900
Common Class A [Member]
Common stock shares authorized			2,750,000,000		500,000,000
Common stock par value | $ / shares	$ 0.0001		$ 0.0001		$ 0.0001						$ 0.0001
Common Shares Outstanding			182,973,780		46,025,754
Common stock shares inculding redemption issued					20,125,000				20,125,000
Common stock shares inculding redemption outstanding					20,125,000				20,125,000
Class of warrants redemption exercise price | $ / shares											$ 11.50
Temporary Equity Outstanding					14,097,169				18,124,262
Pre-closing stock repurchase, net of exercise of vested options (in shares)	183,548	509,602			85,594
Payments for repurchase of common stock | $	$ 22,000				$ 100
Common Class B [Member]
Common stock shares authorized					50,000,000
Common stock par value | $ / shares					$ 0.0001								$ 0.0001
Common Shares Outstanding					5,031,250				5,031,250				4,312,500
Common Class B [Member] | Previously Reported [Member]
Common Shares Outstanding												4,312,500
Common Class B [Member] | Restatement Adjustment [Member]
Common Shares Outstanding												5,031,250

Common Stock - Pre-Closing Stoc

Common Stock - Pre-Closing Stock Repurchase (Details) - USD ($) $ in Thousands	Jan. 20, 2021	Mar. 31, 2021	Mar. 31, 2020
Class of Stock [Line Items]
Payments for repurchase of common stock		$ 22,027	$ 0
Common Class A [Member]
Class of Stock [Line Items]
Stock repurchased and retired during period (in shares)	2,207,580
Payments for repurchase of common stock	$ 22,000
Pre-closing stock repurchase, net of exercise of vested options (in shares)	183,548
Pre-closing stock repurchase, net of exercise of vested options	$ 1,800

Common Stock - Merger Transacti

Common Stock - Merger Transaction (Details)	Jan. 20, 2021$ / sharesshares	Mar. 31, 2021$ / shares	Jan. 19, 2021$ / shares	Dec. 31, 2020$ / shares	Jul. 22, 2019$ / shares
Class of Stock [Line Items]
Recapitalization Exchange Ratio	0.4530	0.4530
Chief Executive Officer [Member]
Class of Stock [Line Items]
Recapitalization Exchange Ratio	0.4530
Common Class A [Member]
Class of Stock [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares	0.0028
Common Class A [Member] | Chief Executive Officer [Member]
Class of Stock [Line Items]
Common stock, par value	$ 0.0001
Common Class A [Member] | Hims Inc [Member]
Class of Stock [Line Items]
Common stock, par value			$ 0.000001
Common Class V [Member]
Class of Stock [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Common Class V [Member] | Hims Inc [Member]
Class of Stock [Line Items]
Common stock, par value			$ 0.000001
Common Class A And V [Member] | Common Stock [Member]
Class of Stock [Line Items]
Recapitalization, contingent consideration, equity, exchange ratio	0.0443

Common Stock - Settlement of No

Common Stock - Settlement of Nonrecourse Related-Party Promissory Notes (Details) - USD ($) $ in Thousands	Jan. 20, 2021	Mar. 31, 2021	Mar. 31, 2020
Class of Stock [Line Items]
Repayment of promissory notes associated with vested and unvested shares		$ 1,193	$ 0
Common Class A [Member] | Common Stock [Member]
Class of Stock [Line Items]
Repayment of promissory notes associated with vested and unvested shares	$ 1,200
Common stock, forfeited (in shares)	370,734

Common Stock - PIPE Investment

Common Stock - PIPE Investment (Details) - PIPE Investment $ / shares in Units, $ in Millions	Jan. 20, 2021USD ($)$ / sharesshares
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	7,500,000
Sale of stock, price per share (in dollars per share) | $ / shares	$ 10
Sale of stock, consideration received on transaction | $	$ 75

Common Stock - Prior to Merger

Common Stock - Prior to Merger (Details) - $ / shares	Jan. 04, 2021	Dec. 31, 2020	Nov. 30, 2020	Jul. 31, 2020
Common Stock Warrants
Class of Warrant or Right [Line Items]
Conversion of convertible securities				143,452
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 0.06
Common Stock Warrants, Group One
Class of Warrant or Right [Line Items]
Conversion of convertible securities			425,146
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 0.06
Vendor Warrants
Class of Warrant or Right [Line Items]
Conversion of convertible securities	380,746	266,522	37,244
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 1.75	$ 1.75	$ 1.75
Common Stock Warrants, Group Two
Class of Warrant or Right [Line Items]
Conversion of convertible securities		178,840
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 0.06

Common Stock - Subsequent to Me

Common Stock - Subsequent to Merger (Details)	Jan. 20, 2021d$ / sharesshares	Feb. 28, 2021shares	Mar. 31, 2021d$ / sharesshares	Dec. 31, 2020$ / shares
Class of Warrant or Right [Line Items]
Recapitalization Exchange Ratio	0.4530		0.4530
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share)	$ 15		$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share)	17.50		17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share)	$ 20		$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days | d	10		10
Reverse recapitalization, contingent consideration, equity, earnout period, threshold consecutive trading days | d	20		20
Reverse recapitalization, contingent consideration, equity, earnout period	5 years		5 years
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 0.01
Public Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 0.10
Common Class A [Member] | Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, outstanding (in shares) | shares	3,012,500	3,012,500
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 11.50
Conversion of convertible securities (in shares) | shares		1,474,145
Common Class A [Member] | Public Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, outstanding (in shares) | shares	6,708,333		6,695,915
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 11.50		$ 11.50
Common Class A [Member] | Parent Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, outstanding (in shares) | shares	888,143		888,143
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 11.50

Common Stock - Schedule of Warr

Common Stock - Schedule of Warrants Outstanding (Details) - $ / shares	Mar. 31, 2021	Jan. 20, 2021	Jan. 04, 2021	Dec. 31, 2020	Nov. 30, 2020
Vendor Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in dollars per share)			$ 1.75	$ 1.75	$ 1.75
Public Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in dollars per share)				$ 0.10
Common Class A [Member] | Vendor Warrants [Member]
Class of Warrant or Right [Line Items]
Shares (in shares)	462,335
Exercise Price (in dollars per share)	$ 1.75
Common Class A [Member] | Debt Warrants [Member]
Class of Warrant or Right [Line Items]
Shares (in shares)	98,723
Exercise Price (in dollars per share)	$ 6.96
Common Class A [Member] | Public Warrants [Member]
Class of Warrant or Right [Line Items]
Shares (in shares)	6,695,915	6,708,333
Exercise Price (in dollars per share)	$ 11.50	$ 11.50
Common Class A [Member] | Parent Warrants [Member]
Class of Warrant or Right [Line Items]
Shares (in shares)	888,143	888,143
Exercise Price (in dollars per share)	$ 11.50

Common Stock - Public Warrant T

Common Stock - Public Warrant Terms (Details) - Common Class A [Member]	3 Months Ended
	Mar. 31, 2021d$ / shares
Public Warrants [Member]
Class of Warrant or Right [Line Items]
Exercisable period after closing date	30 days
Warrant expiration period	5 years
Period after warrants become exercisable for warrant redemption commencement	90 days
Public Warrants, Warrant Redemption [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, redemption price per share (in dollars per share)	$ 0.10
Minimum period of prior notice for share redemption	30 days
Threshold trading days | d	10
Sale price redemption threshold (in dollars per share)	$ 10
Period after written notice of redemption	30 days
Public Warrants, Cash Redemption [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, redemption price per share (in dollars per share)	$ 0.01
Minimum period of prior notice for share redemption	30 days
Threshold trading days | d	20
Sale price redemption threshold (in dollars per share)	$ 18
Threshold consecutive trading days | d	30

Basic and Diluted Net Loss pe_3

Basic and Diluted Net Loss per Share - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Dividends, common stock	$ 0	$ 0
Common Class A [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Number of redeemable shares excluded from calculation of net income (loss) per share (in shares	0	664,162

Basic and Diluted Net Loss pe_4

Basic and Diluted Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator:
Net loss attributable to common stockholders	$ (51,404)	$ (6,033)
Common Class A [Member]
Numerator:
Net loss attributable to common stockholders	$ (49,185)	$ (4,823)
Denominator:
Basic (in shares)	146,471,524	27,668,709
Diluted (in shares)	146,471,524	27,668,709
Basic (in dollars per share)	$ (0.34)	$ (0.17)
Diluted (in dollars per share)	$ (0.34)	$ (0.17)
Common Class V [Member]
Numerator:
Net loss attributable to common stockholders	$ (2,219)
Denominator:
Basic (in shares)	6,609,014
Diluted (in shares)	6,609,014
Basic (in dollars per share)	$ (0.34)
Diluted (in dollars per share)	$ (0.34)
Common Class F [Member]
Numerator:
Net loss attributable to common stockholders		$ (1,210)
Denominator:
Basic (in shares)		6,941,352
Diluted (in shares)		6,941,352
Basic (in dollars per share)		$ (0.17)
Diluted (in dollars per share)		$ (0.17)

Basic and Diluted Net Loss pe_5

Basic and Diluted Net Loss per Share - Schedule of Excluded Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Common stock issued for exercise of stock options subject to nonrecourse promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares	3,545,821	16,855,230
Common stock issued for early exercise of stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares	388,839	154,820
Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares	19,702,603	85,510,700
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares	16,361,955	6,969,701
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares	3,347,300	0
Warrant [Member] | Common Class A [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares	7,733,346	1,895,345
Warrant [Member] | Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares	0	1,433,585

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Effective income tax rate reconciliation, percent	(0.20%)	(0.60%)

Initial Public Offering - Addit

Initial Public Offering - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended
	Jul. 22, 2019USD ($)$ / sharesshares
Over-Allotment Option [Member]
Capital Units Issued | shares	2,625,000
Capital Units Price per Share | $ / shares	$ 10
Proceeds From Capital Units Issuance	$ 201,250
Offering Cost Of Capital Units	11,900
Deferred Underwriting Commission	$ 7,040
IPO [Member]
Capital Units Issued | shares	20,125,000
Common Class A [Member]
Class Of Warrants Exercise Price | $ / shares	$ 11.50

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - shares	Jan. 20, 2021	Feb. 28, 2021
Subsequent Event [Line Items]
Description of change of corporation, name and classification of shares distribution	(i) the Company became a Delaware corporation and, in connection with the Domestication, (A) the Company’s name changed to “Hims & Hers Health, Inc.”, (B) each outstanding Class A ordinary share of the Company and each outstanding Class B ordinary share of the Company became one share of Class A common stock of the Company, and (C) each outstanding warrant of the Company became one warrant to purchase one share of New Hims Class A Common Stock;
Class of warrant or right, exercised after document period		3,012,500
Common Class A [Member]
Subsequent Event [Line Items]
Class of warrant or right, exercised after document period		1,474,145

Restatement of Previously Iss_3

Restatement of Previously Issued Audited and Unaudited Financial Statements - Summary of restatement of balance sheet (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 26, 2019	Apr. 19, 2019
Restatement [Line Items]
Total assets	$ 345,900,000	$ 118,697,000
Liabilities and Shareholders' Equity
Total current liabilities	19,680,000	15,228,000
Deferred legal fees		150,000				$ 150,000
Warrant liability	33,370,000
Total liabilities	53,434,000	15,609,000
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	0	249,962,000
Shareholders' equity:
Ordinary shares value	18,000
Additional paid-in capital	515,216,000	24,429,000
Accumulated deficit	(222,696,000)	(171,292,000)
Total shareholders' equity	292,466,000	(146,874,000)			$ (139,953,000)	$ (139,793,000)
Total liabilities and shareholders' equity	$ 345,900,000	$ 118,697,000
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Shares subject to possible redemption - shares outstanding	0	93,328,118
Common Class A [Member]
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Shares subject to possible redemption - shares outstanding		14,097,169				18,124,262
Ordinary shares - shares issued and outstanding	182,973,780	46,025,754
Common Class B [Member]
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Ordinary shares - shares issued and outstanding		5,031,250				5,031,250			4,312,500
As Previously Reported
Restatement [Line Items]
Total assets		$ 205,633,422	$ 205,813,988	$ 206,200,737	206,287,199	$ 204,765,183	$ 204,094,833
Liabilities and Shareholders' Equity
Total current liabilities		4,896,647	3,037,725	1,167,702	1,167,388	979,394	1,036,867
Deferred underwriting commissions		7,043,750	7,043,750	7,043,750	7,043,750	7,043,750	7,043,750
Deferred legal fees		150,000	150,000	150,000	150,000	150,000	150,000
Total liabilities		12,090,397	10,231,475	8,361,452	8,361,138	8,173,144	8,230,617
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption		188,543,020	190,582,510	192,839,280	192,926,060	191,592,030	190,864,210
Shareholders' equity:
Preferred shares value		0	0	0	0	0	0
Additional paid-in capital		6,901,127	4,861,657	2,604,910	2,518,131	3,852,147	4,579,960
Accumulated deficit		(1,901,752)	137,736	2,394,508	2,481,284	1,147,262	419,439
Total shareholders' equity		5,000,005	5,000,003	5,000,005	5,000,001	5,000,009	5,000,006
Total liabilities and shareholders' equity		$ 205,633,422	$ 205,813,988	$ 206,200,737	$ 206,287,199	$ 204,765,183	$ 204,094,833
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Ordinary shares - shares issued and outstanding		1,270,698	1,066,749	841,072	832,394	965,797	1,038,579
As Previously Reported | Common Class A [Member]
Shareholders' equity:
Ordinary shares value		$ 127	$ 107	$ 84	$ 83	$ 97	$ 104
As Previously Reported | Common Class B [Member]
Shareholders' equity:
Ordinary shares value		$ 503	$ 503	$ 503	$ 503	$ 503	$ 503
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Ordinary shares - shares issued and outstanding								4,312,500
As Previously Reported | Common Stock Subject to Mandatory Redemption [Member]
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Shares subject to possible redemption - shares outstanding		18,854,302	19,058,251	19,283,928	19,292,606	19,159,203	19,086,421
Restatement Adjustment
Liabilities and Shareholders' Equity
Warrant liability		$ 47,571,334	$ 31,902,349	$ 14,380,242	$ 11,329,888	$ 10,349,417	$ 10,840,587
Total liabilities		47,571,334	31,902,349	14,380,242	11,329,888	10,349,417	10,840,587
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption		(47,571,330)	(31,902,350)	(14,380,240)	(11,329,890)	(10,349,410)	(10,840,590)
Shareholders' equity:
Preferred shares value		0	0	0	0	0	0
Additional paid-in capital		33,369,400	17,700,577	178,642	(2,871,677)	(3,852,147)	(4,411,552)
Accumulated deficit		(33,369,881)	(17,700,896)	(178,789)	2,871,565	3,852,036	4,411,446
Total shareholders' equity		$ (4)	$ 1	$ (2)	$ 2	$ (7)	$ 3
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Ordinary shares - shares issued and outstanding		4,757,133	3,190,235	1,438,024	1,132,989	1,034,941	1,084,059
Restatement Adjustment | Common Class A [Member]
Shareholders' equity:
Ordinary shares value		$ 477	$ 320	$ 145	$ 114	$ 104	$ 109
Restatement Adjustment | Common Stock Subject to Mandatory Redemption [Member]
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Shares subject to possible redemption - shares outstanding		(4,757,133)	(3,190,235)	(1,438,024)	(1,132,989)	(1,034,941)	(1,084,059)
As Restated
Restatement [Line Items]
Total assets		$ 205,633,422	$ 205,813,988	$ 206,200,737	$ 206,287,199	$ 204,765,183	$ 204,094,833
Liabilities and Shareholders' Equity
Total current liabilities		4,896,647	3,037,725	1,167,702	1,167,388	979,394	1,036,867
Deferred underwriting commissions		7,043,750	7,043,750	7,043,750	7,043,750	7,043,750	7,043,750
Deferred legal fees		150,000	150,000	150,000	150,000	150,000	150,000
Warrant liability		47,571,334	31,902,349	14,380,242	11,329,888	10,349,417	10,840,587
Total liabilities		59,661,731	42,133,824	22,741,694	19,691,026	18,522,561	19,071,204
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption		140,971,690	158,680,160	178,459,040	181,596,170	181,242,620	180,023,620
Shareholders' equity:
Preferred shares value		0	0	0	0	0	0
Additional paid-in capital		40,270,527	22,562,234	2,783,552	(353,546)		168,408
Accumulated deficit		(35,271,633)	(17,563,160)	2,215,719	5,352,849	4,999,298	4,830,885
Total shareholders' equity		5,000,001	5,000,004	5,000,003	5,000,003	5,000,002	5,000,009
Total liabilities and shareholders' equity		$ 205,633,422	$ 205,813,988	$ 206,200,737	$ 206,287,199	$ 204,765,183	$ 204,094,833
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Ordinary shares - shares issued and outstanding		6,027,831	4,256,984	2,279,096	1,965,383	2,000,738	2,122,638
As Restated | Common Class A [Member]
Shareholders' equity:
Ordinary shares value		$ 604	$ 427	$ 229	$ 197	$ 201	$ 213
As Restated | Common Class B [Member]
Shareholders' equity:
Ordinary shares value		$ 503	$ 503	$ 503	$ 503	$ 503	$ 503
As Restated | Common Stock Subject to Mandatory Redemption [Member]
A Reconciliation Of The ClassA Ordinary Shares Subject To Possible Redemption Outstanding And ClassA Ordinary Shares Outstanding [Abstract]
Shares subject to possible redemption - shares outstanding		14,097,169	15,868,016	17,845,904	18,159,617	18,124,262	18,002,362

Restatement of Previously Iss_4

Restatement of Previously Issued Audited and Unaudited Financial Statements - Summary of restatement statements of operations (Detail) - USD ($)	3 Months Ended					6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2020
Restatement [Line Items]
Loss from operations	$ (48,409,000)			$ (6,218,000)
Change in fair value of warrant liability	(2,681,000)			71,000
Gain on investments (net), dividends and interest, held in Trust Account	(2,905,000)			230,000
Net (loss) income	$ (51,404,000)			$ (6,033,000)
Weighted average shares outstanding, basic and diluted	153,080,538			34,610,061
Basic and diluted net income per share	$ (0.34)			$ (0.17)
Common Class A [Member]
Restatement [Line Items]
Gain on investments (net), dividends and interest, held in Trust Account									$ 1,500,000	$ 1,400,000
Net (loss) income	$ (49,185,000)			$ (4,823,000)
Common Class B [Member]
Restatement [Line Items]
Net (loss) income									(6,000,000)	(40,300,000)
As Previously Reported
Restatement [Line Items]
General and administrative expenses		$ 2,338,004	$ 123,634	246,783	$ 449,938	$ 370,417	$ 466,544	$ 2,708,421	710,080	4,791,727
Loss from operations		(2,338,004)	(123,634)	(246,783)	(449,938)	(370,417)	(466,544)	(2,708,421)	(710,080)	(4,791,727)
Gain on investments (net), dividends and interest, held in Trust Account		81,232	36,858	1,580,805	885,983	1,617,663	885,983	1,698,895	1,857,342	1,742,713
Net (loss) income		$ (2,256,772)	$ (86,776)	$ 1,334,022	$ 436,045	$ 1,247,246	$ 419,439	$ (1,009,526)	$ 1,147,262	$ (3,049,014)
As Previously Reported | Common Class A [Member]
Restatement [Line Items]
Weighted average shares outstanding, basic and diluted		20,125,000	20,125,000	20,125,000	20,125,000	20,125,000	20,125,000	20,125,000	20,125,000	20,125,000
Basic and diluted net income per share			$ 0	$ 0.08	$ 0.04	$ 0.08	$ 0.04	$ 0.08	$ 0.08	$ 0.07
As Previously Reported | Common Class B [Member]
Restatement [Line Items]
Weighted average shares outstanding, basic and diluted		5,031,250	5,031,250	5,031,250	5,031,250	5,031,250	5,031,250	5,031,250	5,031,250	5,031,250
Basic and diluted net income per share		$ (0.46)	$ (0.02)	$ (0.05)	$ (0.09)	$ (0.07)	$ (0.09)	$ (0.54)	$ (0.08)	$ (0.89)
Restatement Adjustment
Restatement [Line Items]
General and administrative expenses					$ 600,675		$ 600,675		$ 600,675
Loss from operations					(600,675)		(600,675)		(600,675)
Change in fair value of warrant liability		$ (17,522,107)	$ (3,050,354)	$ (980,471)	5,012,121	$ (4,030,825)	5,012,121	$ (21,552,932)	5,503,291	$ (37,221,917)
Net (loss) income		(17,522,107)	(3,050,354)	(980,471)	4,411,446	(4,030,825)	4,411,446	(21,552,932)	4,902,616	(37,221,917)
As Restated
Restatement [Line Items]
General and administrative expenses		2,338,004	123,634	246,783	1,050,613	370,417	1,067,219	2,708,421	1,310,755	4,791,727
Loss from operations		(2,338,004)	(123,634)	(246,783)	(1,050,613)	(370,417)	(1,067,219)	(2,708,421)	(1,310,755)	(4,791,727)
Change in fair value of warrant liability		(17,522,107)	(3,050,354)	(980,471)	5,012,121	(4,030,825)	5,012,121	(21,552,932)	5,503,291	(37,221,917)
Gain on investments (net), dividends and interest, held in Trust Account		81,232	36,858	1,580,805	885,983	1,617,663	885,983	1,698,895	1,857,342	1,742,713
Net (loss) income		$ (19,778,879)	$ (3,137,130)	$ 353,551	$ 4,847,491	$ (2,783,579)	$ 4,830,885	$ (22,562,458)	$ 6,049,878	$ (40,270,931)
As Restated | Common Class A [Member]
Restatement [Line Items]
Weighted average shares outstanding, basic and diluted		20,125,000	20,125,000	20,125,000	20,125,000	20,125,000	20,125,000	20,125,000	20,125,000	20,125,000
Basic and diluted net income per share			$ 0	$ 0.08	$ 0.04	$ 0.08	$ 0.04	$ 0.08	$ 0.08	$ 0.07
As Restated | Common Class B [Member]
Restatement [Line Items]
Weighted average shares outstanding, basic and diluted		5,031,250	5,031,250	5,031,250	5,031,250	5,031,250	5,031,250	5,031,250	5,031,250	5,031,250
Basic and diluted net income per share		$ (3.95)	$ (0.63)	$ (0.24)	$ 0.79	$ (0.87)	$ 0.79	$ (4.82)	$ 0.90	$ (8.29)

Restatement of Previously Iss_5

Restatement of Previously Issued Audited and Unaudited Financial Statements - Summary of restatement of cash flows (Detail) - USD ($)	3 Months Ended					6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2020
Restatement [Line Items]
Net (loss) income	$ (51,404,000)			$ (6,033,000)
Net cash used in operating activities	(15,948,000)			(5,191,000)
Net cash provided by (used in) investing activities	(163,324,000)			7,233,000
Net cash provided by financing activities	$ 239,945,000			30,335,000
As Previously Reported
Restatement [Line Items]
Net (loss) income		$ (2,256,772)	$ (86,776)	1,334,022	$ 436,045	$ 1,247,246	$ 419,439	$ (1,009,526)	$ 1,147,262	$ (3,049,014)
Adjustments to reconcile net loss to net cash used in operating activities				(1,580,805)		(1,617,663)	(885,983)	(1,698,895)	(1,857,342)	(1,742,713)
Net cash used in operating activities				(28,639)		(124,809)	(207,200)	(577,740)	(241,682)	(777,074)
Net cash provided by (used in) investing activities							(201,250,000)	325,000	(201,250,000)	325,000
Net cash provided by financing activities							203,238,700		203,002,023
Net change in cash				(28,639)		(124,809)	1,781,500	(252,740)	1,510,341	(452,074)
Non-cash investing and financing activities:
Change in value of Class A ordinary shares subject to possible redemption				1,334,030		1,247,250	190,864,210	(1,009,520)	191,592,030	(3,049,010)
Restatement Adjustment
Restatement [Line Items]
Net (loss) income		(17,522,107)	(3,050,354)	(980,471)	4,411,446	(4,030,825)	4,411,446	(21,552,932)	4,902,616	(37,221,917)
Adjustments to reconcile net loss to net cash used in operating activities				980,471		4,030,825	(4,411,446)	21,552,932	(4,902,616)	37,221,917
Non-cash investing and financing activities:
Change in value of Class A ordinary shares subject to possible redemption				(980,480)		(4,030,830)	(10,840,590)	(21,552,940)	(10,349,410)	(37,221,920)
Initial fair value of warrant liability					(15,852,708)		(15,852,708)		(15,852,708)
As Restated
Restatement [Line Items]
Net (loss) income		$ (19,778,879)	$ (3,137,130)	353,551	4,847,491	(2,783,579)	4,830,885	(22,562,458)	6,049,878	(40,270,931)
Adjustments to reconcile net loss to net cash used in operating activities				(600,334)		2,413,162	(5,297,429)	19,854,037	(6,759,958)	35,479,204
Net cash used in operating activities				(28,639)		(124,809)	(207,200)	(577,740)	(241,682)	(777,074)
Net cash provided by (used in) investing activities							(201,250,000)	325,000	(201,250,000)	325,000
Net cash provided by financing activities							203,238,700		203,002,023
Net change in cash				(28,639)		(124,809)	1,781,500	(252,740)	1,510,341	(452,074)
Non-cash investing and financing activities:
Change in value of Class A ordinary shares subject to possible redemption				$ 353,550		$ (2,783,580)	180,023,620	$ (22,562,460)	181,242,620	$ (40,270,930)
Initial fair value of warrant liability					$ (15,852,708)		$ (15,852,708)		$ (15,852,708)